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When the microtubule (MT)-associated protein tau is not bound to axonal MTs, it becomes
hyperphosphorylated and vulnerable to proteolytic cleavage and other changes typically
seen in the hallmark tau deposits (neurofibrillary tangles) of tau-associated neurode-
generative diseases (tauopathies). Neurofibrillary tangle formation is preceded by tau
oligomerization and accompanied by covalent crosslinking and cytotoxicity, making tan-
gle cytopathogenesis a natural central focus of studies directed at understanding the role
of tau in neurodegenerative disease. Recent studies suggest that the formation of tau
oligomers may be more closely related to tau neurotoxicity than the presence of the tan-
gles themselves. It has also become increasingly clear that tau pathobiology involves a
wide variety of other cellular abnormalities including a disruption of autophagy, vesicle
trafficking mechanisms, axoplasmic transport, neuronal polarity, and even the secretion of
tau, which is normally a cytosolic protein, to the extracellular space. In this review, we
discuss tau misprocessing, toxicity and secretion in the context of normal tau functions
in developing and mature neurons. We also compare tau cytopathology to that of other
aggregation-prone proteins involved in neurodegeneration (alpha synuclein, prion protein,
and APP). Finally, we consider potential mechanisms of intra- and interneuronal tau lesion
spreading, an area of particular recent interest.
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OVERVIEW
Cytotoxicity associated with the accumulation of abnormal pro-
tein aggregates has emerged as a central common mechanism
underlying human neurodegenerative disease. Neurons are unique
among differentiated cell types in that they do not re-enter the cell
cycle and thus cannot use mitosis as a method for clearing abnor-
mally aggregated proteins. As a result, they are inherently vulner-
able to disruption of protein turnover mechanisms such as the
ubiquitin/proteasome pathway and autophagy, especially in aged
individuals. The abnormal turnover of aggregation-prone proteins
such as alpha synuclein (SNCA), prion protein (PrP), amyloid
beta (Ab) peptide, and tau are thus key factors in most (95%)
of the neurodegenerative diseases that affect humans. Protein
aggregation is typically accompanied and potentiated by abnor-
mal phosphorylation, ubiquitination, covalent crosslinking, and
the abnormal activation of autolytic proteases (1–6). A common
feature of such proteins is an “intrinsically disordered” structure
(4), in which the normal conformation can be readily changed into
Abbreviations: AD, Alzheimer’s disease; APP, amyloid precursor protein; CJD
Creutzfeldt–Jacob disease; CNS, central nervous system; CSF, cerebrospinal fluid;
ECF, extracellular fluid; ER, endoplasmic reticulum; FAD, familial AD; GA, Golgi
apparatus; GO, gene ontology; HD, Huntington’s disease; HSPG, heparan sulfate
proteoglycan; LOAD, late onset AD; MAP, microtubule associated protein; MT,
microtubule; MTBR, microtubule binding repeat domain; NDD, neurodegener-
ative disease; NFT, neurofibrillary tangle; NT, neuropil thread; PD, Parkinson’s
disease; PrP, prion protein; PrPSc, misfolded, pathogenic prion protein; SNCA, alpha
synuclein; TGN, trans-Golgi network.
a beta-sheet rich structure with high aggregation propensity (6).
Moreover, conditions in which SNCA (Parkinson’s disease, Lewy
Body Dementia), tau (Corticobasal Degeneration, Pick’s disease,
Frontotemporal Dementia), and PrP [Creutzfeldt–Jakob disease
(CJD), Gerstmann–Straussler–Scheinker disease] form abnormal
aggregates typically show overlapping neuropathology, suggesting
that synergistic interactions may occur between these proteins in
each of these conditions (7). The aggregation of the microtubule
(MT)-associated protein tau, which is heat stable and normally
exhibits a random coil conformation in aqueous solution, plays
a central role in the neurodegeneration seen in Alzheimer’s dis-
ease and non-Alzheimer’s tauopathies that form the core of the
paired helical filament (PHF) (8, 9). PHFs and related filamen-
tous aggregates such as straight and ribbon-like filaments (10)
in turn make up the hallmark tau lesions [neurodegenerative
diseases (NFTs), Pick bodies, etc.] seen in Alzheimer’s disease
and other tauopathies. However it is likely that at least some
of the characteristic features that distinguish tauopathies from
other neurodegenerative syndromes have roots in specific normal
cellular functions of tau.
MT AND NON-MT ASSOCIATED FUNCTIONS OF TAU
Tau is expressed from a single gene on chromosome 17 and is
alternatively spliced to yield six different isoforms in the adult cen-
tral nervous system (CNS). Each of these contains a C-terminal
microtubule binding domain (MTBR) consisting of three or four
tandem repeat motifs. The best understood “normal” function of
tau in mature neurons involves its binding to and stabilizing axonal
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MTs via the MTBR. Tau belongs to a family of microtubule associ-
ated proteins (MAPs) that includes other neuronal proteins such as
MAP1A, MAP1B, and MAP2, and also non-neuronally expressed
members (MAP4). Each of these proteins contains a conserved
region in and around the MTBR that suggests a common origin
via gene duplication. The poor conservation of areas outside of
the MTBR in both mammalian tau family molecules and in tau-
like proteins in various vertebrate and invertebrate species suggests
that they may play species-specific functions.
The regulation of tau-MT binding has been heavily studied
and is now well established. Tau-MT binding associated with MT
stabilization is mediated by the phosphorylation of serine and
threonine residues at sites immediately adjacent to and within
the MTBR by a wide variety of kinases [Ref. (11) for a good
review]. Phosphorylation of the regions flanking the MTBR pro-
duce a stoichiometrically graded reduction in the affinity of tau for
MTs, whereas phosphorylation at specific sites within the MTBR
(Ser262 and Ser356) abolish virtually all tau-MT interactions (12).
Subtleties of tau-MT binding appear to be particularly depen-
dent on the phosphorylation pattern of proline-associated serine
and threonine resides on the N-terminal side of the MTBR by
proline-directed kinases (e.g., CDK5, MAP kinase 1, GSK3b).
It has become clear that tau has functions in addition to axonal
MT stabilization in both mature and developing neurons that
involve alternative binding partners for the MTBR (e.g., actin- and
actin-associated proteins, heparin sulfate proteoglycan) and/or
other parts of the tau molecule, such as the amino terminal projec-
tion domain (13). These functions include the integration of cellu-
lar cytoskeletal functions with interneuronal signaling pathways.
Important developmental functions of tau include various aspects
of axonogenesis, such as the establishment of axonal identity (i.e.,
neuronal polarization) (14) and the subsequent outgrowth (15)
and myelination of developing axons. Each of these developmen-
tal functions involves MTBR interactions with the subcortical actin
network and plasma membrane (16, 17), via either the MTBR itself
[actin – Ref. (18)] or via the N-terminal projection domain, which
interacts with Src family non-receptor tyrosine kinases such as fyn
(13, 19, 20).
DISEASE-ASSOCIATED TAU MODIFICATIONS ARE CORRELATED WITH
THEIR DISSOCIATION FROMMTs
Tau hyperphosphorylation
A key alteration that is associated with NFT formation is the
phosphorylation of multiple serine and threonine residues in
and around the MTBR that normally regulate tau binding to
MTs (hyperphosphorylation). Hyperphosphorylation reversibly
decreases the affinity of tau for MTs (21, 22) and is consistently
seen in PHFs isolated from AD and non-AD tauopathy brains
even at early stages in the development of disease (23–27). Hyper-
phosphorylated tau defined as containing 10 or more moles of
phosphate per tau molecule (28) isolated from AD brains has been
shown to be capable of self-assembly in vitro (29), suggesting that
tau hyperphosphorylation may directly induce aggregate forma-
tion as well as altering the normal functions of tau. Tau muta-
tions associated with frontotemporal dementia with Parkinsonism
linked to chromosome 17 (FTDP-17) increase the rate and amount
of tau phosphorylation and decrease the number of phosphate
groups required for aggregation (11, 28). Although clearly asso-
ciated with PHF formation, hyperphosphorylation may not be a
prerequisite for tau aggregation, since tau constructs containing
only the MTBRs are able to form filaments in the unphospho-
rylated state (29, 30). However, dephosphorylation prevents the
self-assembly of full-length isoforms, suggesting that the N- and
extreme C-terminal regions of tau inhibit this (31, 32). Curi-
ously, phosphorylation of tau at certain residues (Ser262 and Ser
214) that decrease tau-MT affinity act to prevent formation of
PHFs (33). This, together with multiple reports of phosphoryla-
tion state-contingent kinase specificity for individual sites in the
flanking domains, suggests that regulation of both tau:tubulin and
tau:tau affinity by phosphorylation is highly subtle and remains
incompletely understood.
Tau truncation
The evolution of tangle-intrinsic tau from full-length isoforms to
MTBR-only fragments (34) suggests that proteolysis at both the
C and N termini of tau may play a significant role in NFT for-
mation. This is directly supported by a number of studies of tau
filament formation. Temporal analysis of filament formation in
AD brains shows that tau misfolding [recognized by the Alz50
antibody (35)] precedes initial truncation at D421, with subse-
quent truncation at E391 appearing at later stages of the disease
(34). Truncated C-terminal tau fragments can act as nucleation
seeds in vitro, sequestering full-length tau in both mutant and
wild-type forms (11). Such nucleation may be related to con-
formation specific tau:tau interactions that have recently been
proposed to mediate the intercellular propagation of neurofibril-
lary lesions (36, 37). Truncation of tau at E391 has been identified
within the core of PHFs (38) and at D421 in the brains of AD
patients (39). The presence of the C terminal has an inhibitory
effect on polymerization of full-length tau (31) and C-terminal
truncation accelerates tau filament formation in vitro (40–42). A
study using cells expressing the MTBR of tau containing an FTDP-
17 mutation demonstrated that proteolysis of the N and C regions
flanking the MTBR produced aggregation-prone fragments capa-
ble of seeding further aggregation, while blocking N-terminal
truncation of this fragment prevented C-terminal proteolysis, sug-
gesting that this region (near K257) may act to shield downstream
residues (11). It should be noted that although C-terminal trun-
cation is sufficient to cause tau aggregation in cellular models,
additional mechanisms might drive filament formation in dis-
eased neurons. Tangle-bearing neurons in a transgenic mouse
model contained little D421-cleaved tau (43), suggesting that mul-
tiple pathways to aggregate formation are likely active in neurons
affected by tauopathy. This is consistent with the presence of mul-
tiple types of lesions in the various forms of non-AD tauopathy
and in AD brain, where neuropil threads (NTs) occur with or
perhaps even before the onset of NFT formation (44) and with
the characteristic differences in neurofilament content and tau
conformation seen in NTs (45) and Pick bodies (10, 46) versus
NFTs.
Other variables affecting tau aggregation
In addition to phosphorylation and truncation, there are a num-
ber of factors that appear to modulate tau aggregate formation,
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some of which are associated with tauopathy cytopathogenesis.
Foremost among these are the intronic and exonic point and dele-
tion mutations in and around the MTBR that cause familial non-
AD tauopathies [reviewed in Ref. (47)]. The restriction of such
mutations to the MTBR and their ability to drive the neurofibril-
lary pathogenesis of presenile tauopathies constitutes some of the
strongest evidence for the importance of tau aggregation in human
disease. Polyanions such as heparan sulfate proteoglycan (HSPG)
are abnormally distributed in pre-tangle and tangle-bearing neu-
rons and can catalyze the formation of straight filaments and PHFs
in vitro (48, 49) regardless of the phosphorylation state of tau (30,
50, 51). Specific isoforms of tau also differ in their ability to form
filaments in vitro. Different ratios of three and four repeat (3R and
4R) tau isoforms are characteristic of tau aggregates found in spe-
cific tauopathies (26, 52) and the presence of intronic mutations
interfering with the splicing of exon 10 in patients with FTDP-17
(30, 53) confirms that the resulting change in the ratio of 3R:4R
tau is sufficient to drive tau filamentation and neurodegenera-
tion (54). Three and four repeat isoforms differ in characteristics
that may affect their participation in NFT formation, including
the ability to form disulfide bridges (55) and their relative affinity
for MTs and fyn kinase (56). The presence of 3R tau may reduce
the tendency of 4R tau to form filaments (57), possibly by inter-
fering with disulfide bond formation. Finally, the larger cellular
and genetic context is likely to have a significant bearing on the
tendency of tau to aggregate into NFTs. Early cellular changes
involving lysosomal and autophagy pathway abnormalities may
either result from or modulate tau aggregate formation (58, 59).
Genetic factors such as the H1 haplotype, which affects the overall
expression levels of tau and the splicing of exon 10 and possibly
exons 2 and 3 (60), and the presence of ApoE4 allele have been
reported to be associated with high disease incidence (61). Addi-
tional genetic factors that affect tau aggregation and thus disease
propensity include interactions with elements on chromosome 21
that affect tau splicing and the function of non-APP proteins such
as DYRK1A (53, 62) as well as APP itself (63). Overall, tau inter-
actions with non-MT elements via its MTBR and in particular,
tau:tau interactions associated with aggregation and their involve-
ment in tau-mediated neurodegeneration have been a subject of
intensive investigation. However, while a great deal is now known
about both the mechanisms of tau aggregation and the circum-
stances of tau modifications associated with aggregate formation,
it remains unclear exactly how each of these elements contributes
to tau cytopathogenesis. This uncertainty has been exacerbated by
the identification of tau toxicity mechanisms that are not associ-
ated with the MTBR but which may also play important roles in
neurodegeneration.
REACTIVATION OF DEVELOPMENTAL TAU FUNCTIONS IN
NEURODEGENERATION
While tau aggregation is clearly a central factor in tauopathy patho-
genesis, the role tau plays in the development of axonal identity
and other aspects of axonogenesis has increasingly been linked to
neurodegenerative disease mechanisms. These include the appear-
ance of cell cycle markers (64) and ectopically sprouting axonlike
processes (NTs) emerging from the dendrites (45, 65–67) during
the development of neurofibrillary lesions in neurodegenerative
tauopathies. Dendritic NTs in particular suggest that tau func-
tions in the development of axonal identity may play a role in
the early stages of AD where they may reflect damage to mecha-
nisms that maintain the terminally differentiated neuronal state
(68, 69). The “fetal” (3R0N) tau isoform is the shortest three
repeat tau isoform with the lowest binding affinity for MTs (30),
possibly reflecting the far greater importance of tau N-terminal
interactions and functions during development relative to the role
tau plays in the mature CNS. A key tau interactor during devel-
opment is the non-receptor tyrosine kinase fyn, which plays a
critical role in axonal outgrowth and myelination (15, 70). Inter-
actions between the tau N terminus and signaling molecules such
as fyn typically occur in the actin-rich cortical cytoskeleton largely
in the absence of MTs and are necessary for functions such as
growth cone motility (16). Fyn, like tau, localizes to NFTs (20,
71) and is essential to the development and possibly the propa-
gation of Abeta-mediated toxicity in mouse models of AD (72).
Fyn-mediated interactions with tau play a role in the localiza-
tion of a small amount of tau to the plasma membrane (73),
particularly at dendritic loci (74) where it is involved in synaptic
functions associated with learning and memory (75–77). Abnor-
mal interactions of tau with fyn kinase increasingly appear to play
a critical role in membrane-associate tau dysfunction especially
via the generation of synaptotoxic species of Abeta from APP.
This occurs in the context of fyn-mediated phosphorylation of
APP in early endosomes (78) and in turn exacerbates both tau
localization to rafts and tau phosphorylation by fyn (79). Such
correlations suggest that tau mislocalization to dendrites and the
generation of abnormal amounts of Abeta may interact synergis-
tically to produce both cytotoxicity and abnormal developmental
events such as NT growth and cell cycle re-entry (80) in AD
neuropathogenesis.
INTERNEURONAL ASPECTS OF TAUOPATHY
Tau interactions with lipid raft proteins such as fyn and (possi-
bly) APP may be centrally important in two recently emerging
interneuronal aspects of tau pathobiology: (a) tau secretion and
interneuronal transfer via unconventional mechanisms and (b)
tau:tau interactions involved in templated misfolding and “prion-
like” lesion spreading mechanisms. Membrane localization favors
tau oligomerization, which increasingly appears to be a key event
in at least some forms of tau toxicity. Membrane-associated tau
functions mediated by its N terminus appear to be linked to the
diversion of tau from the cytosol to membrane-bound vesicles,
in particular those associated with the trans-Golgi network and
the autophagosome-lysosome pathway (81). As a consequence,
it is likely that both cellular and molecular aspects of interneu-
ronal lesion spreading have their roots in membrane-associated
tau misprocessing mechanisms.
Selective neuronal vulnerability to tau toxicity
Ever since it became apparent in the mid-1980s that Alzheimer’s
disease is a common neurodegenerative condition of the elderly
as opposed to a relatively rare familial syndrome, it has been
clear that the number and distribution of NFTs is strongly cor-
related with progressive cognitive loss (82, 83). There are two
possible mechanisms that might account for disease-associated
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stereotyped patterns of lesion development with increasing disease
severity. One possibility is that loci that are affected early in the
disease sequence are more vulnerable to the mechanisms underly-
ing tau-induced degeneration at the cellular level. A hierarchy of
vulnerability to tau toxicity might then result in a stereotyped
sequence of lesion development over time. One characteristic
shared by brain regions that develop early tau lesions in AD is
synaptic plasticity; highly plastic cortical pyramidal neurons such
as those of the hippocampus are inherently vulnerable to excito-
toxic insults by virtue of their glutamatergic pharmacology and the
prevalence of LTP-associated plasticity mechanisms (84). Selec-
tive vulnerability may also be acquired via injury, as with the
greatly increased risk posed by antecedent head trauma (85–87). It
seems increasingly likely that both intrinsic and extrinsic selective
vulnerability factors interact with lesion spreading mechanisms
associated with synaptic connectivity patterns (discussed at length
below) to produce the variety of clinical syndromes associated with
neurofibrillary degeneration.
Interneuronal movement of misprocessed tau
For many years, the interconnectedness of affected regions and
the highly stereotyped, disease-specific pattern of neurofibrillary
lesion spread within the brain in AD and non-AD tauopathies
has suggested that the actual interneuronal transfer of a toxic
factor must be involved in the progression of neurodegenerative
tauopathies (88–91). The actual movement of toxic tau species
between neurons is now thought by many to be the primary mech-
anism mediating the progressive appearance of tau pathology and
clinical dysfunction in tauopathy, including those associated with
repeated head injury (87). In particular, the templated misfolding
mechanism that mediates the infectivity of prion diseases such
as CJD is increasingly invoked as a model for the interneuronal
transfer of tau-mediated toxicity (36, 92–97), especially in murine
transgenic models of tauopathy (98–100). Evidence that differ-
ent abnormal conformations of PrP may in fact define different
prion-mediated diseases (101, 102) raises the possibility that very
different clinical presentations and neuronal vulnerabilities could
be attributable to molecular level differences in a single protein.
However, the study of tau as a “tauon” [a term for a tau species that
spreads toxicity via templated misfolding coined by Novak et al.
(93)] has been conducted largely in the absence of a cellular context
for the actual transfer of tau between neurons, making it difficult
to connect the molecular mechanisms involved in protein tem-
plating to specific cellular events and mechanisms associated with
tau cytopathology. In particular, while the secretion (103–105) and
uptake (92) of tau itself in cellular models has been demonstrated
and linked to the elevated tau levels in early AD (106), it is unclear
how secretion is related to the spreading of neurofibrillary lesions
and whether that occurs via an oligomer-associated mechanism,
such as templated misfolding or ionophore formation (107, 108),
or via some mechanism that does not require the tau MTBR at
all (109–112). The subtle but important questions that remain
about the relationships between the development of NFTs, toxic
oligomer formation, templated misfolding, N-terminal tau toxic-
ity, and the actual cellular mechanisms responsible for secretion
and uptake of misprocessed tau species will be explored at greater
length below.
CURRENT FOCI OF TAUOPATHY RESEARCH
THE BIOGENESIS OF NEUROFIBRILLARY TANGLES
The development of NFTs, the characteristic tau lesions that
develop in cortical pyramidal neurons during the course of AD, has
been relatively well characterized but is still incompletely under-
stood. NFT development begins with the abnormal phosphoryla-
tion of tau at multiple sites in and around the MTBR, accompanied
by abnormal somatodendritic tau accumulation resulting in the
appearance of pre-fibrillary phosphorylated punctate deposits in
the cell body and dendrites of affected neurons (24, 113). These
eventually form condensed fibrillar deposits near the nucleus and
near dendritic branch points, displacing normal cytoskeletal ele-
ments such as MTs (113, 114). Over time, these fill most of the cell
and take on a characteristic flame-shaped appearance. Eventually,
the neuron containing the NFT dies and the NFT remains as a
“tombstone” lesion or “ghost” tangle.
While all tau isomers and cleavage fragments that contain
the MTBR appear to be capable of forming filaments, their
precise morphology may vary considerably; they can appear as
straight, ribbon-like, or any of a variety of PHF-like structures,
all of which are reproducible under in vitro conditions (10, 46,
115). Moreover, the wide variety of tau modifications that affect
aggregation suggest that considerable subtlety exists in the mech-
anisms responsible for tau assembly. Such factors include the
presence of tauopathy-inducing point mutations (116, 117) the
presence/absence of the C-terminal (31) or N-terminal (10, 32)
domains, and variations in the experimental conditions used
(118). The fact that the range of filaments and aggregate types seen
with human tauopathies can be reproduced in sporadic tauopathy
syndromes without benefit of tau mutations indicate that addi-
tional relevant variables to tau aggregate form come from cellular
factors, such as the inclusion of NFs (Pick bodies) or internal
membrane elements (granulovacuolar degeneration) or even the
shape of the host cell. Understanding how molecular and cellular
factors interact to produce a specific type of aggregate can thus be
seen as an index of our overall grasp of tauopathy pathogenesis.
Direct formation of NFTs from cytosolic tau
A key unresolved issue in NFT formation is the cellular context
in which NFTs form during the course of neurodegenerative dis-
ease. In particular, it is unclear whether NFTs form as a result of
cytosolic or even MT-templated interactions between tau species
or whether NFT formation requires additional cellular elements,
such as membrane-bound vesicles, to occur. The most straightfor-
ward hypothesis of NFT generation and growth is direct assembly
from free tau monomers and/or oligomers in the cytosol. The abil-
ity of tau filaments to form in vitro by MT-templated mechanisms
(119), and the ability of tauopathy mutations to actively disrupt
MT networks (116) as well as favor filament formation (117, 120)
are all consistent with the idea that tau aggregate formation, even-
tually leading to NFTs, begins immediately upon dissociation from
MTs or even by conformational changes that occur in MT-bound
tau. For instance, tau oligomerization has been observed to occur
on the surface of MTs (119), which might then generate cytosolic
tau oligomers capable of directly seeding NFT growth. This seems
to account directly for the granular pre-fibrillary deposits that con-
stitute the earliest visible stage of NFT formation (121, 122) and
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is consistent with in vitro experiments demonstrating that tau fil-
ament assembly resulting in NFT formation is potentiated by tau
interactions with fatty acids and/or polyanionic molecules such as
heparin sulfate proteoglycans and RNA (30, 50, 123, 124). More-
over, electron and atomic force microscopy studies have revealed
numerous intermediates in tau fibril formation, including abnor-
mally folded monomers capable of aggregation (125) and granular
tau aggregates that may be formed from these monomers (121,
122). All of these observations are consistent with the direct for-
mation of NFTs from cytosolic tau oligomers and this mechanism
is therefore widely assumed to account for the biogenesis of most,
if not all, NFTs.
Does vesicle-associated tau contribute to NFT formation?
Studies of tau biology raise the possibility of an alternative (or
perhaps additional) mechanism to direct oligomerization in the
cytosol. The catalysis of tau oligomerization by fatty acids is as
consistent with a membrane-mediated assembly mechanism as it
would be with a cytosol-only mechanism. More direct support
for membrane-mediated NFT formation includes electron micro-
scopic observations of membrane-associated PHFs in AD brain
(126) and the experimental generation of tau filaments in vitro on
the surfaces of anionic micelles (127). This occurs via tau interme-
diates containing β structures whose conformations are dependent
on the presence of the anion and which are capable of seeding
tau fibril formation. Tau that is not associated with MTs interacts
with actin (18) and/or actin-associated proteins (128, 129) caus-
ing misprocessed tau to accumulate under the plasma membrane
and in membrane-bound vesicles in cellular tauopathy models (19,
81, 105, 130, 131). This could plausibly result in tau endocytosis
leading to vesicle-associated tau being returned to the perinu-
clear region via the retromer pathway, followed by NFT formation
via membrane-templated oligomerization (125, 127). The Golgi
apparatus and the autophagy-lysosome pathway are additional
possible sources of tau-bearing vesicles that could contribute to
NFTs. Abnormalities in Golgi structure have been identified both
in association with tau overexpression (132) and with NFTs in AD
brain (133). A recent study of PHF tau uptake in neuronal cultures
suggested that endocytosed tau aggregates eventually form perin-
uclear aggresome-like deposits, which also suggests involvement
of trans-Golgi “retromer” pathways in NFT formation (134). Sim-
ilarly, the disruption of proteasome/macroautophagy (autophagy)
mediated tau turnover is a prominent early element in pre-fibrillar
changes in AD cytopathology (59), as evidenced by the polyubiq-
uitination of tau in NFTs (135). Experimental disruption of lyso-
somal function via chloroquine administration induced lysosomal
accumulation of tau aggregates (136), suggesting that disease-
associated changes might contribute to NFT formation in AD via
a similar mechanism. Similar patterns of somatodendritic tau dis-
tribution and associated signs of toxicity are seen in cortical pyra-
midal neurons with pre-fibrillar tau deposits or nascent NFTs (24,
113, 114, 137). These patterns suggest a role for vesicle-associated
tau in both local tau cytotoxicity and in the generation of NFTs
(81, 138). Examples are shown in Figure 2. In both cases, tau accu-
mulates first in distal, membrane-rich dendritic structures (113,
139) and then at branch points and along dendritic shafts, where
it is correlated with local MT loss, causing varicosities to appear
in dendrites (113, 131). In the lamprey model, which is the only
in situ tauopathy model from which high resolution localization
information is available, these are associated with the accumu-
lation of tau-bearing vesicles (and membrane-bound organelles
such as mitochondria) at either end of the varicosity, suggesting
that they are due to the failure of bidirectional MT mediated trans-
port (Figure 1B). The accumulation of tau-containing vesicles at
dendritic branch points is likely due to the shift in MT polarity
patterns (140) typically found there, which induces the accumu-
lation of vesicular organelles such as mitochondria. This vesicular
build-up may be either the cause or consequence of MT-mediated
transport failure (141–143).
TAU TOXICITY MECHANISMS – ARE NFTs TOXIC?
The widely observed correlation between NFT distribution and
neurodegeneration in nearly all tauopathies including AD (82,
83, 113, 114) has led to the widespread assumption that NFTs
are an integral feature of tau neurotoxicity. Although toxic tau
aggregates are notoriously difficult to generate in cell culture from
wild-type tau isoforms (144), studies with hyperaggregating tau
mutants have demonstrated that cleavage products are toxic when
expressed in culture, with aggregate formation and apoptotic cell
death occurring within 24–48 h of tau expression (145, 146). That
said, it is becoming increasingly evident that NFTs may not be the
agent driving neurotoxicity in whole animal tauopathy models. In
Drosophila, expression of both mutant and wild-type human tau
leads to AD-like pathology (late onset neurodegeneration, selec-
tive toxicity of cholinergic neurons) in the absence of NFTs (147).
In addition, the long time courses (up to 20 years) proposed for
NFT formation based on imaging data from AD brain (148–150)
are not consistent with direct causality between NFTs and tau tox-
icity. While NFT growth is largely irreversible in inducible mouse
tauopathy models, more dynamic aspects of tau toxicity are clearly
reversible (151–154), suggesting that the mature NFT itself is much
less toxic than the events associated with building it. Dendritic
and axonal changes associated with tau accumulation and NFT
formation in both transgenic mice (155) and AD brains (114, 156)
appear to be correlated with abnormal mitochondrial distribu-
tion, which in turn recruits low ATP and Ca++mediated toxicity
mechanisms (144). Ca++ mediated tau toxicity is also suggested
by the effects of specific tauopathy mutations on Ca++ channel
properties (55) and high resolution correlations between localized
secretion, MT loss, and accumulations of vesicular tau (81, 131) as
illustrated in Figure 1. These findings and others have complicated
our understanding of the relationship between NFT distribution
and abundance and the actual toxicity mechanisms driving human
neurodegenerative disease. Recent studies have also tended to dis-
sociate degenerative cellular changes from NFT formation. It has
even been suggested that large tau aggregates such as NFTs may
serve a neuroprotective role (157, 158), preventing hyperphospho-
rylated tau from sequestering normal, MT-bound tau. Studies in
other tauopathy models have also called into question the role
played by hyperphosphorylation in the chain of events leading to
degeneration; recent fly model studies (159) have suggested that
hyperphosphorylation can be neuroprotective by blocking other
aspects of tau toxicity, such as apoptotic changes associated with
cell cycle re-entry (80, 160).
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FIGURE 1 | Accumulation of vesicular tau in ABC dendrites and at
dendritic branch points causes local transport failure, MT loss, and
localized secretion from dendrites. High resolution confocal imaging of
somatodendritic tau accumulation in the lamprey tauopathy model suggests a
cellular mechanism to account for the relationship between localized tau
toxicity, somatodendritic MT loss, and the pattern of NFT evolution in
pyramidal neurons as described by Braak et al. (113), Braak and Braak (137),
and Blazquez-Llorca et al. (139). (A) Cell body (left) and dendritic branch point
(center) of a lamprey ABC expressing full-length 4R0N human tau bearing the
P301L tauopathy mutation before the onset of tau-induced degeneration. Tau
is triple labeled: MT associated (Tau5, green channel), MT dissociated (9G3,
blue channel), and total tau (GFP epitope tag red channel). Tau phosphorylated
at Y18 (pY18 tau or 9G3 positive MT dissociated tau) is accumulating at the
base of large dendrites and at branch points, a pattern typical of
MT-transported vesicles (asterisks). The rightmost panel shows pY18 tau
accumulating at either end of dendritic varicosities (arrows). (B) Left panels
show pY18 distribution in non-degenerating (Stage 1) and degenerating
(Stage 2) ABC dendrites. Distally transported tau is distributed throughout
distal (but not proximal) dendrites in non-degenerating cells, but becomes
localized to dendrite branch points and varicosities with the onset of
degeneration [arrows – see Refs (81, 165)]. Center and right: Dendritic
beading is caused by the localized failure of MT mediated transport, resulting
in the accumulation of pY18 (fyn phosphorylated) tau associated with vesicles
and membrane-bound organelles. The accumulation of mitochondria (COX2
label) is particularly well marked. With the onset of dendritic degeneration,
total and pY18+ tau accumulates at each end and eventually in the center of
dendritic varicosities in what appear to be MT-transported vesicles. The
localized secretion occurring in the vicinity of such deposits suggests that
tau-bearing vesicles first destabilize the MTs responsible for their transport,
accumulate in the resulting varicosities and are then secreted. While the
mechanism responsible for this has not been demonstrated directly, the
concomitant loss of MTs and localized secretion suggests a Ca++ flux
mediated mechanism. (C) A model for vesicle-associated tau in NFT
formation and cytodegeneration. Failure of tau to become axonally localized
and bind axonal MTs results in actin association and endocytosis (1).
Tau-bearing vesicles are transported both distally and proximally on dendritic
MTs, accumulating at dendritic branch points (where MT polarity patterns
favor localized cargo accumulation Aronov 01) and near synaptic terminals (2),
where it may become locally toxic possibly via interacting with Abeta in
synapse-associated endosomes, resulting in structural failure of dendrites
(top right) and uptake by afferents resulting in retrograde trans-synaptic
movement. Synaptic activity may also result in the centripetal transport of
tau-bearing vesicles to the Golgi apparatus (3) where it may modulate NFT
formation. Scale bars: (A): 20µ, (B) 100µ (left), 5µ (right).
Oligomer-associated toxicity mechanisms
Tau oligomers have been the most widely proposed candidate
for the toxic intermediate species in NFT biogenesis responsible
for the correlation between neurofibrillary lesions and neurode-
generation in AD and non AD tauopathies (83). The toxicity of
oligomeric tau is suggested by numerous correlative studies (161)
and in particular with respect to the dynamic effects of tau aggre-
gation; for instance, the concentration of tau multimers (162) but
not large aggregates or monomers (95) in the brains of tauopathy
mice are correlated with memory and cognitive deficits.
Oligomer-mediated membrane permeability changes. The
structural similarity between amyloid proteins associated with
neurodegeneration supports the existence of a common toxic-
ity mechanism based on common properties of such proteins
such as their propensity for oligomerization and close associa-
tion with membrane. The toxicity of amyloid oligomers unrelated
to neurodegenerative diseases suggests that a specific, shared con-
formation may be responsible, with toxicity being mediated by
mitochondrial dysfunction associated with an increase in reactive
oxygen species (141, 163). Oligomers of several different amyloids
cause an increase in ion conductance across lipid bilayers (164)
raising the possibility that they might alter or the permeability of
the plasma membrane, resulting in increased internal [Ca++] and
associated toxic changes. Both Ab and SNCA can form oligomeric
structures that increase ion permeability of synthetic vesicular
membranes and which may allow them to create pores within
cell membranes (107). Leakage of cellular contents across the
plasma membrane in SH-SY5Y cells was observed after the exter-
nal application of tau oligomers (108), suggesting a similar toxicity
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Gendreau and Hall Tangles, toxicity, and tau secretion
mechanism for tau. These results collectively suggest that tau
oligomers may mediate any of several toxicity mechanisms associ-
ated with Ca++ dysregulation or abnormal generation of reactive
oxygen species. Such changes are typically seen with excitotoxi-
city and mitochondrial dysfunction, both of which appear to be
important elements of AD-associated neurotoxicity (141). Studies
FIGURE 2 |The context of exosomal tau secretion and transneuronal
neurodegeneration. (A) Connectivity diagrams summarizing proteomic
analysis of the exosomal proteome associated with tau overexpression
from neuroblastoma cell cultures (106) using the String online dataset
(104). GO term analysis shows that exosomal tau secretion involves factors
with known links to tau misprocessing (APP, oligomerization, Wnt pathway)
and also suggests the involvement of mechanisms with less established
and no apparent links to tau, AD, and exosomes. Of the ∼660 proteins
identified, 50 were both present on the AlzGene list
(http://www.alzgene.org/) of 616 AD related proteins and had clear links
(0.4 confidence or more (104)) to tau and/or exosomal markers (CD9 and
CD81 were not present in our set, but were part of the probe query) – see
ExoCarta (239) via the String 9.05 connectivity algorithm. Note the strong
linkage to tau (MAPT – shown as a black circle for reference). (B) Another
group (right diagram) consisted of internally connected proteins that did not
have clear functional links to tau on String (confidence <0.4 or not
detected). These nonetheless had significant signals for AD, PD, and HD
that were tightly linked to mitochondrial markers, suggesting the
association of abnormal autophagy with tau secretion, and with synaptic
plasticity (LTP, LDP). All terms shown reflect significant enrichment
(p<0.001) by the String algorithm. (C) Connectivity diagram from
GeneMANIA (http://www.genemania.org) showing physical interactions
between proteins isolated from exosomes using the same set as shown in
(A). In order to identify proteins typically localized to exosomes, we scored
each protein for the number of times it appeared in the nearly 70 different
mammalian exosomal datasets at ExoCarta. Links between tau and highly
exosome associate proteins (dark green icons), mildly exosome associated
(light green icons), and aggregation-prone proteins such as SNCA and APP
(Abeta) are shown as well to illustrate the plausibility of tau diversion to
exosomes in the context of these co-purified proteins. (D) Expression of
4R0N tau in lamprey ABCs produces dendritic localization of tau (red
channel), dendritic degeneration, and localized focal secretion (left box,
orange label) as shown in a confocal micrograph after 10 days of expression
(81). Immunolabel for LC3/MAP1b (green channel) shows cytoskeletal
localization in non-transfected giant axons (seen in cross section – ax), and
in circumferential axons (arrow axon). One of the latter has taken up
secreted tau shown at higher magnification (right) and is exhibiting toxicity
in the form of varicosities (arrows) similar to those shown in ABC dendrites
(dendrite, center). Highly co-localized tau (blue channel) shows cleaved,
autophagosome-associated LC3II associated with tau (arrows) in a pattern
similar to that seen for dendritic mitochondria in Figure 1B. Scale bar: 50µ
(left), 10µ (right). (E) Consensus sets of 1575 downregulated and 1383
upregulated proteins in both LOAD (238) and early onset FAD (237).
(F) Schematic outlining a hypothesis of AD cytopathogenesis that accounts
for tau associated exosomal secretion and downregulation of synaptic and
axonal proteins in AD (red) in the context of current knowledge. Likely
triggers for tau secretion and trans-synaptic lesion spreading (blue) may
occur either directly from the axon due to loss of axonal MT integrity and
secretion regulation, or indirectly from dendrites as the results of toxicity
caused by somatodendritic tau accumulation.
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Gendreau and Hall Tangles, toxicity, and tau secretion
in cellular tauopathy models showing a correlation between local-
ized cytotoxicity, tau membrane association, and localized MT loss
(81, 130, 165) are consistent with this (see examples in Figure 2), as
is the presence at the plasma membrane of polyanionic molecules
known to catalyze tau oligomer/filament formation such as HSPGs
(30, 166) and RNA (123).
Oligomers as prions. The “prionlike” toxicity and propagation
mechanisms recently proposed for tau may be considered as a
special category of oligomer-mediated toxicity, if one makes the
assumption that a prionlike misfolded tau conformation would be
toxic and would propagate in a manner similar to that of the PrP
itself. However, despite the considerable amount of research effort
devoted to understanding the relationship between propagation
and toxicity mechanisms of the PrP, this relationship remains quite
unclear. Mutant forms of PrP that do not create large amounts of
misfolded, pathogenic prion protein (PrPSc) with high beta-sheet
content in plaques have still been shown to generate CJD-like syn-
dromes in mice (167). Moreover, interference with the normal GPI
linkage that anchors PrP to the membrane can affect the ability of
the mutant form to propagate interneuronally and generate a clin-
ical syndrome but without affecting local cytotoxicity (168). Tau
misprocessing appears to have a number of parallels to PrP toxicity
in this regard; like PrP, tau oligomerization, and post-translational
modifications that favor tau oligomer formation (e.g., hyperphos-
phorylation, truncation) are closely associated with toxicity. In
the case of tau, it remains unclear whether higher-level oligomers
and/or polymers propagate interneuronally in human tauopathies.
Recent studies using murine tauopathy models have suggested that
they are capable of this (98, 99, 169).
Disruption of protein turnover pathways. The dysfunction of
proteasomal, autophagosomal, and lysosomal pathways with pro-
tein aggregate formation in tauopathy is a candidate for mediating
tau toxicity as well as NFT formation, and may play an important
role in the development of other tau containing cellular lesions,
such as granulovacuolar degeneration [Ref. (170), reviewed in Ref.
(171)] in which tau accumulations appear to be membrane associ-
ated. The polyubiquitinated state of NFT-tau suggests involvement
of the ubiquitin-proteasome pathway (135). Additionally, the co-
localization of tau aggregates with high concentrations of acid
hydrolases in granulovascular degeneration (GVD) bodies in the
hippocampal neurons of AD patients suggests that they may be
the result of incomplete autophagy (172, 173). Lysosomal activa-
tion is also observed in cultured cells transfected with mutant tau
and in mice expressing mutant tau transgenes (174). Inhibition
of lysosomal proteases by tau misprocessing causes the accumula-
tion of amphisome-resembling vacuoles in cultured neurons that
are morphologically similar to those seen in AD brains. Inhibition
of vesicular transport by tau, especially N-terminal tau fragments
(175) may also prevent the fusion of autophagosomes and lyso-
somes (176), causing the retention of tau-bearing autosomes in
axons and dendrites, where their accumulation may result in
localized degeneration and even tau secretion [Figure 2, also see
Ref. (81)]. One way that dysfunction of the autophagy-lysosomal
machinery caused by tau aggregates may induce toxicity is enhanc-
ing tau oligomerization by the generation of hyperaggregating
tau cleavage fragments due to the incomplete activity of lyso-
somal proteases. Cathepsin L has been shown to generate
aggregation-prone fragments mutant but not wild-type tau via
association with Lamp2A and Hsc70 on the cytosolic face of the
lysosomal membrane (177). Tau-induced disruption of autophagy
may also recruit synergistic effects related to the production of
Abeta from APP, since PS1 is also necessary for autophagosome-
lysosome fusion and lysosomal proteolysis (178). It should also be
noted that the vesicle trafficking pathways associated with aggre-
some formation may also become abnormally involved in tauopa-
thy as demonstrated by a recent study in which tau aggregates were
endocytosed and then localized to perinuclear deposits (134).
Non-oligomer-mediated tau toxicity mechanisms
Receptor-mediated toxicity. An alternative to oligomer/aggregate
associated mechanisms of tau toxicity to explain the selective vul-
nerability of neurons and spread of NFTs through synaptically
connected regions in Alzheimer’s disease is toxicity in response to
tau binding to extracellular receptors, especially those for synap-
tic transmitters such as glutamate and acetylcholine. Tau is toxic
to neurons in culture when applied extracellularly (179), appar-
ently via the generation of Ca++ fluxes via the activation of M1
and M3 muscarinic acetylcholine receptors (180), which bind tau
with a greater affinity than acetylcholine. This is consistent with
the preferential distribution of muscarinic acetylcholine recep-
tors on entorhinal and hippocampal pyramidal neurons, and
accounts for their vulnerability in early stages of Alzheimer’s dis-
ease (181). Interestingly, the dephosphorylation of secreted tau
by tissue-non-specific alkaline phosphatase could potentiate its
high-affinity binding to muscarinic receptors of nearby neurons
(182), thus accounting for the “clustering” lesion spread patterns
characteristically seen in tauopathies (90, 91, 183).
The generation of Ca++ fluxes via receptor-mediated toxic-
ity need not directly involve aggregate or oligomer formation as
a variety of MTBR− tau species appear to form multiple toxic
fragments via Ca++mediated activation of calpains and caspases
in neuroblastoma cultures (109, 184) in at least some cases by
NMDA receptor activation (109). A well studied fragment gener-
ated by calpain activity is a 17-kDa N-terminal fragment consisting
of tau residues 45–230; this is toxic when applied to aged primary
hippocampus cells and when expressed in the brains of transgenic
Drosophila and in ABCs in the lamprey tauopathy model (142, 185,
186). The 17-kDa fragment is elevated in cortical neurons of AD
and tauopathy patients that exhibit increased calpain activity (112)
and is unusual among toxic tau species in its ability to produce neu-
ritic pathology in neuroblastoma lines (185). However, it remains
unclear if the 17-kDa fragment produced by calpain cleavage is a
cause of neuronal death in tauopathy (187). Another N-terminal
tau fragment with a molar mass of 20–22 kDa was found enriched
specifically in the synaptosomes of AD brains in comparison to
control brains (184). When overexpressed in primary rat neurons,
an N-terminal tau fragment containing residues 26–44 impaired
mitochondrial function and caused neuronal death (188). Down-
regulation of calpains in a tauopathy model of Drosophila was
associated with decreased neurodegeneration (186). Both the tau
N-terminal domain and fyn-tau interactions are associated with
the mechanism of Ab toxicity that is mediated by the presence of
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tau (63, 74, 111), as are many fragments generated by similarly
activated caspases (189, 190).
Can “prionic” and receptor-mediated N-terminal tau toxicity
coexist? The ability of tau to mediate Ab toxicity in the absence
of the MTBR (111, 190) and the potential for NFTs to act as neuro-
protective agents (157, 158, 191) raise questions about how large a
role tau aggregate toxicity plays as a direct agent of neurodegenera-
tion, at least in AD (112, 192). The links between toxic N-terminal
tau fragments and excitotoxicity are consistent with the known
vulnerability of cortical neurons with glutamatergic inputs and
high levels of synaptic plasticity to AD (84) and the strong asso-
ciation between Ab mediated toxicity in early stage disease with
synaptic dysfunction (193), suggesting that oligomer toxicity is not
necessarily required for neurodegenerative disease pathogenesis.
We recently pointed out that receptor-mediated toxicity mech-
anisms could account for neurofibrillary lesion propagation via
Ca++mediated activation of calpains and caspases, which could
(at least in theory) generate both NFTs and secretable toxic frag-
ments in downstream neurons, which could then repeat the cycle.
Ironically, such a mechanism would technically fulfill the require-
ments of the original Prion Hypothesis, which makes no mention
of templated misfolding (194). It thus seems safe to say that coex-
istence is not only possible but necessary given what we know
(and don’t know) about how tau toxicity actually operates in
neurodegenerative disease.
TAU SECRETION
Cellular mechanisms of tau secretion
Tau secretion by neurons via multiple biologically distinct path-
ways has been demonstrated both in culture and in situ (105, 106,
195), despite its lack of a signal peptide and of lipidation or GPI
anchor sites that would permit its secretion via the conventional
ER/Golgi route. Tau resembles other aggregation-prone proteins
with key roles in neurodegenerative disease (i.e., SNCA, PrP, and
Ab) in that it is secreted at least in part via the exosome path-
way (106, 196–198); however the full range of secretion routes
and their significance to tauopathy pathogenesis remain unclear.
Human tau phosphorylated at Thr181 (epitope AT270) is secreted
in exosomes in culture and is also found in exosomes in the cere-
brospinal fluid (CSF) of early stage AD patients (106). The early
appearance of exosomal CSF tau in AD argues strongly in favor
of CSF-tau biogenesis by active secretion rather than passive post-
mortem release, since it occurs at a stage (Braak Stage 3) when
neurofibrillary degeneration is restricted to a small proportion of
the brain (199). The N terminal of tau, which interacts with the
plasma membrane and membrane-associated proteins, is required
for secretion in culture and in an in situ lamprey model (195),
where tau secretion occurred in two distinct patterns depending
on the presence of the MTBR,a pattern consistent with the CSF-tau
species observed in AD (200). In the lamprey model, N-terminal
tau species lacking the MTBR become distributed in a diffuse,
gradient-like pattern with secretion occurring from the soma,
while full-length tau was secreted from the dendrites in discrete
foci (195), where it set up much steeper tissue gradients, suggesting
a role for interactions between the tau MTBR and extracellular
matrix elements in the distribution of extracellular tau that could
have relevance to interneuronal tau toxicity patterns and lesion
spreading mechanisms (81). Interestingly, the secreted tau in the
lamprey model is largely dephosphorylated, which is consistent
with the phosphatase activity described by Diaz-Hernandez and
co-workers (182), although no overt toxicity to non-expressing
cells was observed. Secreted tau cleaved at the C terminal has been
observed in cell culture (105), and in transgenic mouse models
expressing human tau as well (201, 202). One of these studies sug-
gested that cleavage at D421 as well as phosphorylation increased
the rate of tau secretion (203), which is consistent with the low
level oligomerization observed in exosomal tau purified from CSF
samples (106).
The method(s) by which tau undergoes secretion remain elu-
sive, although most evidence supports an unconventional secre-
tion pathway resulting in the release of tau in membrane-bound
vesicles (81, 106, 195, 203), where it is favored by the absence of the
MTBR and/or the E2/E3 inserts in the secreted tau species (195).
The failure of 4R2N tau to localize to and be secreted via exosomes
is consistent with this as well (134), as are recent demonstrations
that minute amounts of full-length, non-vesicle-associated tau can
be released by induced forebrain iPS cells in culture (204). Such
findings are consistent with a specific, non-universal release mech-
anism for tau that is associated with exosomes, as is the failure of
an earlier study to detect exosomal tau secretion from healthy
cortical neurons (205). Vesicle-free tau secretion has also been
reported from neuroblastomas (106, 204) and may also occur in
the lamprey tau secretion model (195). It thus remains possible
that the presence of non-vesicular tau in the extracellular space in
any model is due to post-secretion release of tau from exosomes or
other microvesicles (105, 106, 195, 201, 202). Conversely, it could
be that the presence of tau in exosomes may be due to the passive
adherence of extracellular tau to exosomes that have already been
released. This seems unlikely, given: (a) the restriction to E2− tau
seen for exosomal tau and (b) the degree of interconnectivity of
exosomal proteins associated with E2− overexpression via both
functionally (Figure 2C) and via observed physical interactions
(Figure 2C). Overexpression of tau in culture causes cells to secrete
exosomes containing tau that has been phosphorylated at several
proline-directed sites (106), possibly as a protective response to
high concentrations of membrane-associated tau (206). Overall,
it appears that tau may be secreted via multiple mechanisms from
neurons in tauopathy, including microvesicle shedding, exosomal
secretion via endocytosis and fusion with multivesicular bodies,
and exophagy, a pathway involving the diversion of autophago-
somes to exosomes (69, 81, 134, 207). Uptake mechanisms into
trans-synaptic and adjacent cells have been characterized in even
less detail that have tau secretion pathways. In the lamprey sys-
tem, uptake has largely mirrored the“focal” and“diffuse” secretion
mechanisms, with specificities for MTBR+ and tauopathy muta-
tions and MTBR−, E2− tau respectively. A recent study of PHF
tau uptake found evidence for perinuclear localization of tau in
aggresome-like bodies (134), which is consistent with the scheme
suggested in Figure 1. While the uptake of tau aggregates has
been addressed by a number of recent studies directed at “prion-
like” interneuronal transmission mechanisms via oligomeric tau
species, the general mechanisms that might mediate tau uptake
have not yet been characterized in detail in cell culture.
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Interneuronal propagation of tau lesions and prions
Injection of brain extract from mutant human tau P301S trans-
genic mice into the brains of mice expressing wild-type human
tau caused aggregation of wild-type tau in anatomically connected
regions of the brain at a distance from the inoculation site (169).
Sequential progression of tau aggregation (but not the transfer of
individual tau molecules) between synaptically connected regions
of the brain was later confirmed in mouse models in which human
tau expression was spatially limited to synaptically connected areas
of known vulnerability to neurofibrillary degeneration such as
the entorhinal (98) and cingulate cortices (99). Further studies
using antibodies specific to oligomerized tau have demonstrated
that pre-fibrillar tau in AD brain is in fact oligomeric (208) and
that tau oligomers derived from the brains of AD patients can
recruit endogenous tau to oligomers both in vitro (97) and in vivo
(96) and that intracerebral injection of oligomeric but not fibrillar
wild-type tau caused aggregate formation from endogenous tau in
synaptically connected but distant areas (96). Interestingly, regions
receiving propagated tau in this study do not exhibit signs of tau
toxicity, unlike SNCA, which did mediate toxicity as well as protein
propagation via oligomer inoculation (100), a finding that illus-
trates the current ambiguous status of the“tauon”both as a toxicity
agent and as a lesion spreading mechanism. In cell culture models,
intercellular movement of misprocessed tau between cells and the
apparent transfer of conformational alterations to endogenous tau
has been more directly demonstrated. Endocytic tau uptake (veri-
fied using dextran co-localization) followed by fibril formation was
observed in the proximity of labeled aggregates, suggesting recruit-
ment of endogenous tau (92). Double immunolabeling (36) and
fluorescence resonance energy transfer (37) has confirmed associ-
ation of internalized tau with newly formed aggregates composed
of endogenous tau. The uptake and axonal transport (retrograde
and anterograde) of exogenous full-length tau aggregates has since
been reported in differentiated primary neurons grown in Camp-
enot chambers (209). Uptake was described as occurring via a
process resembling bulk endocytosis, with the internalized tau
associated with general lysosomal and endosomal markers (209).
Common features of both cellular and mouse model observations
of prionlike tau transfer include a specificity for oligomeric tau
species and a requirement for the tau MTBR. The successful use
of the 4R2N tau isoform for oligomer propagation (36) and the
uptake of MTBR-only tau species (92) are obviously very different
from the N-terminal specific E2− favored pattern observed for
tau secretion in the lamprey model and in NB2A and M1C neu-
roblastoma cells (195). It should be noted that these differences
reflect the tightly focused nature of the question being posed in
the “prion” studies, i.e., whether oligomeric tau could be shown to
propagate its oligomeric conformation between cells by recruiting
endogenous tau in the recipient cell in the manner now established
for misfolded PrP. This is very likely relevant to the one point of
agreement between these approaches – that tauopathy mutations
favor trans-synaptic tau transfer – since this type of movement
may well be associated with oligomerization.
Recent investigations into interneuronal aspects of tauopathy
pathogenesis have suffered from a bifurcated focus on either:
(1) “prionlike” mechanisms of lesion spreading in terms of tem-
plated misfolding mechanisms derived from our understanding
of prion diseases at either the whole animal or molecular level or
(2) the morphological changes associated with tau secretion in cell
autonomous models. These disparate approaches have (inevitably)
been limited by: (a) their strict focus on molecular mechanism at
the expense of cellular context and (b) exclusion of biochemi-
cal methodology in favor of spatial co-localization (respectively).
These differences have dictated the choice of experimental models
suited to the experimental approach taken (e.g., transgenic mice or
lampreys), but have resulted in largely non-overlapping datasets
devoid of a common context with which to consider them. This
problem is exacerbated by a notable peculiarity of tau biology –
its sensitivity to the terminally differentiated neuronal state. The
inability of experimenters to induce tau-specific toxicity responses
in cell lines (144) is likely due to the greater dependence of tau
toxicity on axonal and synaptic functions relative to other “dis-
ease” proteins that are readily toxic in culture (210). While this
has until now been a formidable obstruction to finding a broad-
based approach to the characterization of mechanisms underlying
tau toxicity and lesion spreading, it offers important hints for the
direction of future studies on the topic – i.e., to focus on synaptic
functions and developmental axon identity and guidance mech-
anisms to identify tauopathy-specific mechanisms, and to focus
on aggregation-mediated mechanisms for identifying common
themes of neurodegenerative disease pathogenesis.
IS SYNAPTIC DYSFUNCTION THE POINT AT WHICH TAU
OLIGOMERIZATION, AUTOPHAGY DISRUPTION, TAU SECRETION, AND
TAU TOXICITY MEET?
While the means by which tau becomes membrane associated and
then diverted into unconventional secretion pathways is not yet
clear, the interaction between tau and fyn kinase and the effects
of that interaction on synaptic function is emerging as a key
feature that might provide clarity. Fyn is rapidly localized to mem-
brane raft domains by virtue of its double lipidation anchor sites
(211). Fyn is capable of inducing exocytosis and/or endocytosis of
membrane localized proteins (212, 213) and binds tau strongly
via its proline rich region (19). Interactions between tau, fyn,
and actin potentiate fyn-driven endocytosis of lipid raft markers
flotillin-1 and flotillin-2 (129, 214). As shown in Figure 1, the Y18
residue of tau, a fyn substrate, is phosphorylated in distal dendritic
vesicle accumulations localized to sites of focal tau secretion via
microvesicles that contain both pY18 tau and endogenous fyn (81).
This offers direct support for a mechanism by which fyn-activated
endocytosis of raft domains containing tau results in localized tau
secretion via unconventional pathways, one of which is exosomes.
The phosphorylation of membrane and vesicle-associated tau by
tauopathy-associated kinases (e.g., GSK3b, MARK kinases, and
fyn) and their association with the exosome pathway is consistent
with both receptor-mediated and oligomer-associated spreading
and toxicity mechanisms, especially in the context of synaptic
dysfunction.
Mislocalized tau and synaptotoxicity at glutamatergic synapses
Toxicity resulting from overexpression or extracellular application
of N-terminal tau fragments in primary neurons appears to be
caused at least in part by NMDA receptor-mediated Ca++ dysreg-
ulation (109), suggesting a potential link between Ca++mediated
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transmitter release, tau secretion and plasticity-associated exci-
totoxicity and the dendritic accumulation of misprocessed tau
at postsynaptic densities. A central role in this interaction may
be mediated by fyn, particularly at highly plastic, glutamatergic
synapses. NMDA receptor activity at glutamatergic synapses may
mediate the tau-induced dendritic degeneration seen in lamprey
ABCs, where fyn associates with and phosphorylates dendritically
localized tau, resulting in both localized MT loss and tau secre-
tion (81). Fyn-mediated activation of NMDA receptors normally
appears to prevent excitotoxicity at glutamatergic synapses that
exhibit LTP and LTD (77), but this mechanism may be vulnerable
to disruption by abnormal perisynaptic tau accumulations (74,
215) and may account for the increased resistance to Ab-induced
excitotoxicity observed in tau-reduced mice (216). Both the P301S
(217) and P301L tauopathy mutations (75) in mice cause changes
in hippocampal synaptic transmission and plasticity well before
the onset of neuronal loss. This is consistent with the dependence
of Ab toxicity on tau at synapses that exhibit plasticity (218) and
suggests a modulatory role for both tau and Ab in synaptic plastic-
ity that could increase sensitivity to excitotoxicity with the onset
of neurodegenerative disease (216), accounting for the selective
vulnerability of the hippocampus in AD. Similarly, mislocalized
tau may also disrupt the AMPA receptor recycling associated with
NMDA receptor activation via an increase in fyn-tau association
and as a resulting increase in the rate of internalization of AMPA
receptors on dendritic spines (77).
Chemical induction of LTD under conditions that prevent
autophagosome/lysosome fusion causes LC3II-positive puncta to
build up in dendritic spines, suggesting a link between AMPA
recycling and autophagy (219). This could provide another point
of access for misprocessed tau to toxicity and secretion mecha-
nisms in AD, since inhibition of lysosomal acidification and/or
the increased generation of Ab associated with PSEN1 mutations
associated with AD can increase Wnt signaling (220) as well as
induce the collection of tau aggregates in lysosomes (221). Tau
overexpression in both cell culture (136) and in situ tauopathy
models (81) causes this as well, leading to the recruitment of both
GSK3b, MARK and fyn kinases, which are all key mediators of
Wnt pathway activity and tauopathy-associated tau kinases (222).
This is consistent with the aberrant Wnt activity seen in AD (223)
and the tau-dependent nature of Ab-induced toxicity via LTP
in hippocampal synapses (218). Moreover, inhibition of GSK3b
decreases the number of GR1 AMPA receptor subunits on the
cell surface and increases their intracellular concentration (224).
This pathway requires endocytosis of GSK3b into multivesicu-
lar bodies (225, 226). This provides potential links between the
NMDA/fyn-mediated endocytosis of AMPA receptors seen with
LTD (227–229) and the recruitment of tau into unconventional
secretion pathways.
A unifying hypothesis
The tau accumulation at or near synapses that accompanies its
mislocalization to dendrites and phosphorylation by GSK3b in
tauopathy could easily potentiate the sequestration of both GSK3b
and tau to late endosomes. This could result in increased sensi-
tivity to LTP associated excitotoxicity (216) and the diversion of
GSK3b (and tau) to exosomes, resulting in exosome-mediated tau
secretion [(106) – also see Figure 2]. This mechanism is consistent
with the increased exosome release (230) and tau secretion (231)
seen with glutamate-induced AMPA and NMDA receptor activ-
ity and the decreased presence of postsynaptic AMPA receptors
in the dendritic spines of P301 tauopathy mice (232). It is also
consistent with the disruption of axonogenesis mechanisms in AD
(such as those involving Wnt activity) and tau oligomerization,
which may help recruit endosomal tau into exosomes (106, 233),
as well as the observed distribution to and effects of tau in the
dendrites in various model systems (78, 81, 234–236). Interest-
ingly, we recently found that all of the major players in the above
hypothetical scenario (Wnt markers, GSK3b, tau, fyn, MARK1,
autophagy markers and NMDA, AMPA, and cholinergic recep-
tor subunits) are enriched in exosomes released by neuroblastoma
cells overexpressing full-length exon 2− (4R0N) human tau iso-
form (Figure 2A). Moreover, somatodendritic tau accumulation
in the lamprey model appears to induce retrograde trans-synaptic
localization toxicity accompanied by the cleavage and localization
of LC3II to autophagosomes (Figure 2D). Such observations are
consistent with a hypothesis in which misprocessed tau that has
been dissociated from MTs and mislocalized to dendrites accu-
mulates via fyn-dependent localization at postsynaptic densities
and is then endocytosed and diverted to exosomes. The key ele-
ment in this hypothesis is an endocytosis-associated mechanism
that depends on tau-fyn interaction, induces tau oligomerization
and is potentiated by both the activity of excitotoxicity-prone
synapses and the progressive failure of tau to segregate normally
to the axon in tauopathy pathogenesis, which increases the expo-
sure of dendritic elements to tau, thereby amplifying perisynaptic
tau toxicity [Ref. (69), also see Figure 2F]. The potential impor-
tance of changes in neuronal differentiation state to tau toxicity
was recently underscored by a study of changes in gene regulation
in two separate cohorts of early onset AD patients (237). They
found that downregulated genes were preferentially associated
with synaptic function and axonal identity, whereas upregulated
genes were preferentially involved in the control of the cell cycle
and in gene expression. We compared their results with those of
an earlier study (238), which reported similar findings in LOAD
patients. GO term analysis of a consensus set of down and upreg-
ulated proteins common to these studies (Figure 2E) are highly
consistent with a failure of axonal and synaptic functions in the
context of de-differentiation (possibly driven by cell cycle re-entry)
producing a synergistic amplification of dendritic tau toxicity, a
hypothesis outlined in more detail elsewhere (69). We therefore
propose that tau secretion and toxicity via synapse-associated dis-
ruption of the TGN by mislocalized tau in dendrites may serve as
a unifying idea that links multiple elements of tau pathobiology
and that provides a context for better understanding the role of
oligomerization in tau toxicity and lesion spreading.
CONCLUSION
The increased appreciation of the significance of tau oligomeriza-
tion in mediating tau neurotoxicity over the past decade must be
counted as a major advance in our understanding of neurodegen-
erative disease. Increased understanding of the inherent toxicity
of oligomers and the ability of at least some of them to induce the
oligomerization of monomeric tau species, raises the possibility
www.frontiersin.org October 2013 | Volume 4 | Article 160 | 11
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gendreau and Hall Tangles, toxicity, and tau secretion
that the prionlike propagation of abnormal tau conformations
may play a role in the spreading of tau lesions in the brain and that
the complex process of oligomer and fibril formation may generate
multiple toxic tau conformations that may have different mecha-
nisms of action. However, it is not known if all oligomers are toxic
and the toxicity mechanism of oligomeric tau remains obscure.
Moreover, we have also learned that N-terminal tau fragments
that are incapable of oligomerization can indeed be toxic and can
mediate Ab-induced toxicity in the absence of the tau MTBR.
Ironically, NFTs themselves do not appear to be toxic in many cir-
cumstances and may even be the result of a neuroprotective cell
response that permits the long-term survival of neurons that bear
them. While significant progress has been made on understand-
ing disease-associated tau oligomerization and NFT biogenesis,
it seems clear that not enough is yet known about the cellular
mechanisms responsible for either tau secretion or tau toxicity
for us to understand the relative significance of conformation
specific or receptor-mediated tau cytopathology in models to
the spreading of neurofibrillary tau lesions and neurodegenera-
tion in human disease. Indeed, it remains possible that both N-
and C-terminal fragments generated by incomplete tau proteol-
ysis might act as synergistic prionlike vectors in a chain-reacting
“Sorcerer’s Apprentice” scenario that could potentially account for
sporadic tauopathy lesion patterns that are poorly explained by an
oligomer mediated mechanism alone. Obviously, the operation
of any mechanism generating multiple toxic N- and C-terminal
tau fragments from a single molecule remains to be elucidated
and cannot be evaluated seriously without far more knowledge of
tau cell biology that we currently possess. Learning how phenom-
ena such as exosomal (and non-exosomal) tau secretion and tau
lesion propagation fit with tau-specific disease features linked to
axonal identity and synaptic plasticity in more detail will mark
a major step toward understanding the roles tau oligomers and
other misprocessed tau species play in human disease.
REFERENCES
1. Avila J. Tau phosphorylation and
aggregation in Alzheimer’s dis-
ease pathology. FEBS Lett (2006)
580:2922–7. doi:10.1016/j.febslet.
2006.02.067
2. Sergeant N, Bretteville A, Ham-
dane M, Caillet-Boudin ML,
Grognet P, Bombois S, et al.
Biochemistry of tau in Alzheimer’s
disease and related neuro-
logical disorders. Expert Rev
Proteomics (2008) 5(2):207–24.
doi:10.1586/14789450.5.2.207
3. Stoothoff W, Johnson GV.
Tau phosphorylation: physio-
logical and pathological con-
sequences. Biochim Biophys
Acta (2005) 1739(2–3):280–97.
doi:10.1016/j.bbadis.2004.06.017
4. Uversky VN. Neuropathology,
biochemistry, and biophysics of
alpha-synuclein aggregation. J
Neurochem (2007) 103(1):17–37.
doi:10.1111/j.1471-4159.2007.
04764.x
5. Caughey B, Baron GS, Chesebro
B, Jeffrey M. Getting a grip on
prions: oligomers, amyloids, and
pathological membrane interac-
tions. Annu Rev Biochem (2009)
78:177–204. doi:10.1146/annurev.
biochem.78.082907.145410
6. Hall GF. What is the link between
protein aggregation and interneu-
ronal lesion propagation in neu-
rodegenerative disease? In: Chang
R, editor. Neurodegenerative Dis-
eases – Processes, Prevention, Pro-
tection and Monitoring. Rijeka,
Croatia: InTech (2011). p. 1–17.
doi:10.5772/27973
7. Clinton LK, Blurton-Jones M,
Myczek K, Trojanowski JQ,
LaFerla FM. Synergistic inter-
actions between Abeta, tau,
and alpha-synuclein: acceler-
ation of neuropathology and
cognitive decline. J Neurosci
(2010) 30(21):7281–9. doi:10.
1523/JNEUROSCI.0490-10.2010
8. von Bergen M, Barghorn S, Bier-
nat J, Mandelkow EM, Mandelkow
E. Tau aggregation is driven by
a transition from random coil to
beta sheet structure. Biochim Bio-
phys Acta (2005) 1739:158–66. doi:
10.1016/j.bbadis.2004.09.010
9. Binder LI, Guillozet-Bongaarts
AL, Garcia-Sierra F, Berry RW.
Tau, tangles, and Alzheimer’s
disease. Biochim Biophys Acta
(2005) 1739:216–23. doi:10.1016/
j.bbadis.2004.08.014
10. King ME, Ghoshal N, Wall JS,
Binder LI, Ksiezak-Reding H.
Structural analysis of Pick’s
disease-derived and in vitro-
assembled tau filaments. Am J
Pathol (2001) 158:1481–90. doi:
10.1016/S0002-9440(10)64099-0
11. Wang JZ, Grundke-Iqbal I, Iqbal
K. Kinases and phosphatases and
tau sites involved in Alzheimer
neurofibrillary degeneration.
Eur J Neurosci (2007) 25:59–68.
doi:10.1111/j.1460-9568.2006.
05226.x
12. Biernat J, Gustke N, Drewes G,
Mandelkow EM, Mandelkow
E. Phosphorylation of Ser262
strongly reduces binding of tau to
microtubules: distinction between
PHF-like immunoreactivity and
microtubule binding. Neuron
(1993) 11:153–63. doi:10.1016/
0896-6273(93)90279-Z
13. Brandt R, Leger J, Lee G.
Interaction of tau with the
neural plasma membrane
mediated by tau’s amino-
terminal projection domain. J
Cell Biol (1995) 131:1327–40.
doi:10.1083/jcb.131.5.1327
14. Caceres A, Kosik KS. Inhibi-
tion of neurite polarity by tau
antisense oligonucleotides in pri-
mary cerebellar neurons. Nature
(1990) 343:461–3. doi:10.1038/
343461a0
15. Biernat J, Wu YZ, Timm T,
Zheng-Fischhofer Q, Mandelkow
E, Meijer L, et al. Protein kinase
MARK/PAR-1 is required for neu-
rite outgrowth and establishment
of neuronal polarity. Mol Biol Cell
(2002) 13:4013–28. doi:10.1091/
mbc.02-03-0046
16. DiTella M, Feiguin F, Morfini G,
Caceres A. Microfilament asso-
ciated growth cone component
depends upon tau for its intra-
cellular localization. Cell Motil
Cytoskeleton (1994) 29:117–30.
doi:10.1002/cm.970290204
17. Zmuda JF, Rivas RJ. Actin disrup-
tion alters the localization of tau
in the growth cones of cerebellar
granule neurons. J Cell Sci (2000)
113(Pt 15):2797–809.
18. He HJ, Wang XS, Pan R, Wang DL,
Liu MN, He RQ. The proline rich
domain of tau plays a role in inter-
actions with actin. BMC Cell Biol
(2009) 10:81. doi:10.1186/1471-
2121-10-81
19. Lee G, Newman ST, Gard DL, Band
H, Panchamoorthy G. Tau inter-
acts with src-family non-receptor
tyrosine kinases. J Cell Sci (1998)
111(Pt 21):3167–77.
20. Lee G, Thangavel R, Sharma
VM, Litersky JM, Bhaskar K,
Fang SM, et al. Phosphoryla-
tion of tau by fyn: implications
for Alzheimer’s disease. J Neurosci
(2004) 24:2304–12. doi:10.1523/
JNEUROSCI.4162-03.2004
21. Bramblett GT, Goedert M, Jakes
R, Merrick SE, Trojanowski JQ,
Lee VM. Abnormal tau phospho-
rylation at Ser396 in Alzheimer’s
disease recapitulates development
and contributes to reduced micro-
tubule binding. Neuron (1993)
10:1089–99. doi:10.1016/0896-
6273(93)90057-X
22. Iqbal K, Zaidi T, Bancher C,
Grundke-Iqbal I. Alzheimer
paired helical filaments. Restora-
tion of the biological activity by
dephosphorylation. FEBS Lett
(1994) 349:104–8. doi:10.1016/
0014-5793(94)00650-4
23. Grundke-Iqbal I, Iqbal K, Tung
YC, Quinlan M, Wisniewski HM,
Binder LI. Abnormal phosphoryla-
tion of the microtubule-associated
protein tau in Alzheimer cytoskele-
tal pathology. Proc Natl Acad Sci U
SA (1986) 83:4913–7. doi:10.1073/
pnas.83.13.4913
24. Bancher C, Brunner C, Lassman
H, Budka H, Jellinger K, Wiche G,
et al. Accumulation of abnormally
phosphorylated tau precedes the
formation of neurofibrillary tan-
gles in Alzheimer’s disease. Brain
Res (1989) 477:90–9. doi:10.1016/
0006-8993(89)91396-6
25. Morishima-Kawashima M,
Hasegawa M, Takio K, Suzuki
M, Yoshida H, Watanabe A, et
al. Hyperphosphorylation of tau
in PHF. Neurobiol Aging (1995)
16:365–80. doi:10.1016/0197-
4580(95)00027-C
26. Buee L, Delacourte A. Compara-
tive biochemistry of tau in pro-
gressive supranuclear palsy, cor-
ticobasal degeneration, FTDP-17
and Pick’s disease. Brain Pathol
(1999) 9:681–93. doi:10.1111/j.
1750-3639.1999.tb00550.x
Frontiers in Neurology | Neurodegeneration October 2013 | Volume 4 | Article 160 | 12
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gendreau and Hall Tangles, toxicity, and tau secretion
27. Buee L, Bussiere T, Buee-Scherrer
V, Delacourte A, Hof PR. Tau
protein isoforms, phosphoryla-
tion and role in neurodegener-
ative disorders. Brain Res Rev
(2000) 33:95–130. doi:10.1016/
S0165-0173(00)00019-9
28. Alonso AC, Mederlyova A, Novak
M, Grundke-Iqbal I, Iqbal K.
Promotion of hyperphospho-
rylation by frontotemporal
dementia mutations. J Biol
Chem (2004) 279:34873–81.
doi:10.1074/jbc.M405131200
29. Alonso AC, Zaidi T, Novak
M, Grundke-Iqbal I, Iqbal K.
Hyperphosphorylation induces
self-assembly of tau into tangles
of paired helical filaments/straight
filaments. Proc Natl Acad Sci
U S A (2001) 98:6923–8.
doi:10.1073/pnas.121119298
30. Goedert M, Jakes R, Spillan-
tini MG, Hasegawa M, Smith
MJ, Crowther RA. Assembly of
microtubule-associated protein
tau into Alzheimer-like filaments
induced by sulphated gly-
cosaminoglycans. Nature (1996)
383:550–3. doi:10.1038/383550a0
31. Abraha A,Ghoshal N,Gamblin TC,
Cryns V, Berry RW, Kuret J, et al. C-
terminal inhibition of tau assem-
bly in vitro and in Alzheimer’s
disease. J Cell Sci (2000) 113(Pt
21):3737–45.
32. Horowitz PM, LaPointe N,
Guillozet-Bongaarts AL, Berry
RW, Binder LI. N-terminal frag-
ments of tau inhibit full-length
tau polymerization in vitro.
Biochemistry (2006) 45:12859–66.
doi:10.1021/bi061325g
33. Schneider A, Biernat J, von
Bergen M, Mandelkow E, Man-
delkow EM. Phosphorylation that
detaches tau protein from micro-
tubules (Ser262, Ser214) also pro-
tects it against aggregation into
Alzheimer paired helical filaments.
Biochemistry (1999) 38:3549–58.
doi:10.1021/bi981874p
34. Guillozet-Bongaarts AL, Garcia-
Sierra F, Reynolds MR, Horowitz
PM, Fu Y, Wang T, et al. Tau
truncation during neurofibrillary
tangle evolution in Alzheimer’s
disease. Neurobiol Aging (2005)
26:1015–22. doi:10.1016/j.
neurobiolaging.2004.09.019
35. Carmel G, Mager EM, Binder
LI, Kuret J. The structural
basis of monoclonal antibody
Alz50’s selectivity for
Alzheimer’s disease pathol-
ogy. J Biol Chem (1996) 271:
32789–95. doi:10.1074/jbc.271.51.
32789
36. Guo JL, Lee VM. Seeding of
normal tau by pathological tau
conformers drives pathogenesis
of Alzheimer-like tangles. J Biol
Chem (2011) 286:15317–31. doi:
10.1074/jbc.M110.209296
37. Kfoury N, Holmes BB, Jiang H,
Holtzman DM, Diamond MI.
Trans-cellular propagation of tau
aggregation by fibrillar species. J
Biol Chem (2012) 287:19440–51.
doi:10.1074/jbc.M112.346072
38. Novak M, Kabat J, Wischik CM.
Molecular characterization of the
minimal protease resistant tau unit
of the Alzheimer’s disease paired
helical filament. EMBO J (1993)
12(1):365–70.
39. Gamblin TC, Berry RW, Binder
LI. Tau polymerization: role of
the amino terminus. Biochem-
istry (2003) 42:2252–7. doi:10.
1021/bi0272510
40. Rissman RA, Poon WW, Blurton-
Jones M, Oddo S, Torp R, Vitek
MP, et al. Caspase-cleavage of tau
is an early event in Alzheimer dis-
ease tangle pathology. J Clin Invest
(2004) 114:121–30. doi:10.1172/
JCI20640
41. Yin H, Kuret J. C-terminal
truncation modulates both
nucleation and extension
phases of tau fibrillization.
FEBS Lett (2006) 580(1):211–5.
doi:10.1016/j.febslet.2005.11.077
42. de Calignon A, Fox LM, Pitstick
R, Carlson GA, Bacskai BJ, Spires-
Jones TL, et al. Caspase activa-
tion precedes and leads to tangles.
Nature (2010) 464:1201–4. doi:10.
1038/nature08890
43. Lin WL, Dickson DW, Sahara N.
Immunoelectron microscopic and
biochemical studies of caspase-
cleaved tau in a mouse model of
tauopathy. J Neuropathol Exp Neu-
rol (2011) 70:779–87. doi:10.1097/
NEN.0b013e31822ac9c9
44. Ghoshal N, Garcia-Sierra F, Wuu
J, Leurgans S, Bennett DA, Berry
RW, et al. Tau conformational
changes correspond to impair-
ments of episodic memory in
mild cognitive impairment and
Alzheimer’s disease. Exp Neurol
(2002) 177:475–93. doi:10.1006/
exnr.2002.8014
45. Perry G, Kawai M, Tabaton
M, Onorato M, Mulvihill P,
Richey P, et al. Neuropil threads
of Alzheimer’s disease show a
marked alteration of the normal
cytoskeleton. J Neurosci (1991)
11(6):1748–55.
46. Arima K. Ultrastructural char-
acteristics of tau filaments in
tauopathies: immuno-electron
microscopic demonstration of
tau filaments in tauopathies.
Neuropathology (2006) 26:475–83.
doi:10.1111/j.1440-1789.2006.
00669.x
47. Goedert M, Jakes R. Muta-
tions causing neurodegenerative
tauopathies. Biochim Biophys Acta
(2005) 1739:240–50. doi:10.1016/
j.bbadis.2004.08.007
48. Fischer D, Mukrasch MD, Biernat J,
Bibow S, Blackledge M, Griesinger
C, et al. Conformational changes
specific for pseudophosphoryla-
tion at serine 262 selectively impair
binding of tau to microtubules.
Biochemistry (2009) 48:10047–55.
doi:10.1021/bi901090m
49. Mukrasch MD, Biernat J, von
Bergen M, Griesinger C, Man-
delkow E, Zweckstetter M.
Sites of tau important for
aggregation populate {beta}-
structure and bind to micro-
tubules and polyanions. J Biol
Chem (2005) 280:24978–86.
doi:10.1074/jbc.M501565200
50. Perez M, Valpuesta JM, Medina
M, Montejo de Garcini E, Avila
J. Polymerization of tau into fila-
ments in the presence of heparin:
the minimal sequence required for
tau-tau interaction. J Neurochem
(1996) 67:1183–90. doi:10.1046/j.
1471-4159.1996.67031183.x
51. Dudek SM, Johnson GV. Trans-
glutaminase catalyzes the for-
mation of sodium dodecyl
sulfate-insoluble, Alz-50-reactive
polymers of tau. J Neurochem
(1993) 61:1159–62. doi:10.1111/j.
1471-4159.1993.tb03636.x
52. Sergeant N, David JP, Lefranc
D, Vermersch P, Wattez A, Dela-
courte A. Different distribution
of phosphorylated tau protein
isoforms in Alzheimer’s and Pick’s
diseases. FEBS Lett (1997) 412:
578–82. doi:10.1016/S0014-
5793(97)00859-4
53. Liu F, Gong C. Tau exon 10 alterna-
tive splicing and tauopathies. Mol
Neurodegener (2008) 3:8. doi:10.
1186/1750-1326-3-8
54. Liu F, Liang Z, Wegiel J, Hwang
YW, Iqbal K, Grundke-Iqbal I, et
al. Overexpression of Dyrk1A con-
tributes to neurofibrillary degener-
ation in Down syndrome. FASEB J
(2008) 22:3224–33. doi:10.1096/fj.
07-104539
55. Furukawa Y, Kaneko K, Nukina
N. Tau protein assembles into
isoform- and disulfide-dependent
polymorphic fibrils with dis-
tinct structural properties. J Biol
Chem (2011) 286:27236–46. doi:
10.1074/jbc.M111.248963
56. Bhaskar K, Yen SH, Lee G.
Disease-related modifications
in tau affect the interaction
between fyn and tau. J Biol
Chem (2005) 280:35119–25.
doi:10.1074/jbc.M505895200
57. Adams SJ, DeTure MA, McBride
M, Dickson DW, Petrucelli L.
Three repeat isoforms of tau
inhibit assembly of four repeat
tau filaments. PLoS One (2010)
5:e10810. doi:10.1371/journal.
pone.0010810
58. Cataldo AM, Hamilton DJ, Nixon
RA. Lysosomal abnormalities in
degenerating neurons link neu-
ronal compromise to senile plaque
development in Alzheimer disease.
Brain Res (1994) 640:68–80. doi:
10.1016/0006-8993(94)91858-9
59. Nixon RA, Wegiel J, Kumar A,
Yu WH, Peterhoff C, Cataldo A,
et al. Extensive involvement of
autophagy in Alzheimer disease:
an immuno-electron microscopy
study. J Neuropathol Exp Neurol
(2005) 64(2):113–22.
60. Strittmatter WJ, Saunders AM,
Schmechel D, Pericak-Vance M,
Enghild J, Salvesen GS, et al.
Apolipoprotein E: high-avidity
binding to beta-amyloid and
increased frequency of type 4 allele
in late-onset familial Alzheimer
disease. Proc Natl Acad Sci U S
A (1993) 90:1977–81. doi:10.1073/
pnas.90.5.1977
61. Caffrey T, Joachim C, Wade-
Martins R. Haplotype-specific
expression of the N-terminal
exons 2 and 3 at the human
MAPT locus. Neurobiol Aging
(2008) 29:1923–9. doi:10.1016/j.
neurobiolaging.2007.05.002
62. Wegiel J, Gong CX, Hwang YW.
The role of DYRK1A in neu-
rodegenerative diseases. FEBS J
(2011) 278:236–45. doi:10.1111/j.
1742-4658.2010.07955.x
63. Rapoport M, Dawson HN, Binder
LI, Vitek MP, Ferreira A. Tau is
essential to beta-amyloid-induced
neurotoxicity. Proc Natl Acad Sci U
SA (2002) 99:6364–9. doi:10.1073/
pnas.092136199
64. Vincent I, Zheng J, Dickson DW,
Kress Y, Davies P. Mitotic phospho-
epitopes precede paired helical fila-
ments in Alzheimer’s disease. Neu-
robiolAging (1998) 19:287–96. doi:
10.1016/S0197-4580(98)00071-2
65. Ihara Y. Massive somatodendritic
sprouting of cortical neurons in
Alzheimer’s disease. Brain Res
(1988) 459:138–44. doi:10.1016/
0006-8993(88)90293-4
66. Braak H, Braak E. Neuropil
threads occur in dendrites of
www.frontiersin.org October 2013 | Volume 4 | Article 160 | 13
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gendreau and Hall Tangles, toxicity, and tau secretion
tangle-bearing nerve cells. Neu-
ropathol Appl Neurobiol (1988)
14:39–44. doi:10.1111/j.1365-
2990.1988.tb00864.x
67. Yamaguchi H, Nakazato Y, Shoji
M, Ihara Y, Hirai S. Ultrastruc-
ture of the neuropil threads in
the Alzheimer brain: their den-
dritic origin and accumulation
in the senile plaques. Acta Neu-
ropathol (1990) 80:368–74. doi:10.
1007/BF00307689
68. Hall GF. The biology and patho-
biology of tau protein. In: Kaval-
laris M, editor. The Cytoskeleton
and Human Disease (Vol. 15).
New York, NY: Springer (2012).
p. 285–313.
69. Bhatia N, Hall GF. Untangling the
role of tau in AD – a unifying
hypothesis. Transl Neurosci (2013)
4(2):117–33. doi:10.2478/s13380-
013-0114-5
70. Belkadi A, LoPresti P. Truncated
tau with the Fyn-binding domain
and without the microtubule-
binding domain hinders the myeli-
nating capacity of an oligoden-
drocyte cell line. J Neurochem
(2008) 107:351–60. doi:10.1111/j.
1471-4159.2008.05600.x
71. Ho GJ, Hashimoto M, Adame A,
Izu M, Alford MF, Thal LJ, et al.
Altered p59Fyn kinase expression
accompanies disease progression
in Alzheimer’s disease: implica-
tions for its functional role. Neu-
robiol Aging (2005) 26:625–35.
doi:10.1016/j.neurobiolaging.
2004.06.016
72. Lambert MP, Barlow AK, Chromy
BA, Edwards C, Freed R, Liosatos
M, et al. Diffusible, nonfibrillar lig-
ands derived from AA 1-42 are
potent central nervous system neu-
rotoxins. Proc Natl Acad Sci U S
A (1998) 95:6448–53. doi:10.1073/
pnas.95.11.6448
73. Usardi A, Pooler AM, Seereeram
A, Reynolds CH, Derinderen
P, Anderton B, et al. Tyro-
sine phosphorylation of tau reg-
ulates its interactions with fyn
SH2 domains, but not SH3
domains,altering the cellular local-
ization of tau. FEBS J (2011)
278:2927–37. doi:10.1111/j.1742-
4658.2011.08218.x
74. Ittner LM, Ke YD, Delerue F,
Bi M, Gladbach A, van Eersel
J, et al. Dendritic function of
tau mediates amyloid-â toxicity in
Alzheimer’s disease mouse mod-
els.Cell (2010) 142:387–97. doi:10.
1016/j.cell.2010.06.036
75. Boekhoorn K, Terwel D, Bie-
mans B, Borghgraef P, Wiegert
O, Ramakers GJ, et al. Improved
long-term potentiation and mem-
ory in young tau-P301L transgenic
mice before onset of hyperphos-
phorylation and tauopathy. J Neu-
rosci (2006) 26:3514–23. doi:10.
1523/JNEUROSCI.5425-05.2006
76. Kremer A, Maurin H, Demedts
D, Devijver H, Borghgraef P, Van
Leuven F. Early improved and late
defective cognition is reflected by
dendritic spines in tau P301L mice.
J Neurosci (2011) 31:18036–47.
doi:10.1523/JNEUROSCI.4859-
11.2011
77. Mondragon-Rodriguez S,
Trillaud-Doppia E, Dudilot
A, Bourgeois C, Lauzon M,
Leclerc M, et al. Interaction of
endogenous tau protein with
synaptic proteins is regulated by
N-methyl-D-aspartate receptor-
dependent tau phosphorylation. J
Biol Chem (2012) 287:32040–53.
doi:10.1074/jbc.M112.401240
78. Zempel H, Thies E, Mandelkow
E, Mandelkow E. Abeta oligomers
cause localized Ca2+ elevation,
missorting of endogenous tau
into dendrites, tau phospho-
rylation, and destruction of
microtubules and spines. Neuro-
biol Dis (2010) 30(36):11938–50.
doi:10.1523/JNEUROSCI.2357-
10.2010
79. Hernandez P, Lee G, Sjoberg M,
Maccioni RB. Tau phosphoryla-
tion by cdk5 and fyn in response
to amyloid peptide Abeta (25-
35): involvement of lipid rafts. J
Alzheimers Dis (2009) 16:149–56.
doi:10.3233/JAD-2009-0933
80. Yang Y, Mufson EJ, Herrup K.
Neuronal cell death is preceded
by cell cycle events at all stages
of Alzheimer’s disease. J Neurosci
(2003) 23(7):2557–63.
81. Lee S, Kim W, Li Z, Hall G. Accu-
mulation of vesicle-associated
human tau in distal dendrites
drives degeneration and tau
secretion in an in situ cellular
tauopathy model. Int J Alzheimers
Dis (2012) 2012:172837.
doi:10.1155/2012/172837
82. Braak H, Braak E. Neuropatho-
logical staging of Alzheimer-
related changes. Acta Neuropath
(1991) 82:239–59. doi:10.1007/
BF00308809
83. Arriagada PA, Growdon JH,
Hedley-White ET, Hyman BT.
Neurofibrillary tangles but not
senile plaques parallel duration
and severity of Alzheimer’s dis-
ease. Neurology (1992) 42:631–9.
doi:10.1212/WNL.42.3.631
84. Arendt T. Disturbance of neuronal
plasticity is a critical pathogenetic
event in Alzheimer’s disease. Int J
Dev Neurosci (2001) 19:231–45.
doi:10.1016/S0736-5748(01)
00007-7
85. Gavett BE, Stern RA, Cantu RC,
Nowinski CJ, McKee AC. Mild
traumatic brain injury: a risk factor
for neurodegeneration. Alzheimers
Res Ther (2010) 2(3):18. doi:10.
1186/alzrt42
86. McKee AC, Cantu R, Nowinski
CJ, Hedley-Whyte ET, Gavett BE,
Budson AE, et al. Chronic trau-
matic encephalopathy in athletes:
progressive tauopathy after repeti-
tive head injury. J Neuropathol Exp
Neurol (2009) 68:709–35. doi:10.
1097/NEN.0b013e3181a9d503
87. McKee AC, Stein TD, Nowin-
ski CJ, Stern RA, Daneshvar
DH, Alvarez VE, et al. The
spectrum of disease in chronic
traumatic encephalopathy. Brain
(2013) 136(Pt 1):43–64. doi:10.
1093/brain/aws307 23208308
88. Saper CB, Wainer B, German DC.
Axonal and transneuronal trans-
port in the transmission of neu-
rological disease: potential role
in system degenerations, includ-
ing Alzheimer’s disease. Neuro-
science (1987) 23:389–98. doi:10.
1016/0306-4522(87)90063-7
89. Su JH, Deng G, Cotman CW.
Transneuronal degeneration in
the spread of Alzheimer’s disease
pathology: immunohistochemical
evidence for the transmission of
tau hyperphosphorylation. Neuro-
biol Dis (1997) 4:365–75. doi:10.
1006/nbdi.1997.0164
90. Armstrong RA, Cairns NJ, Lantos
PL. Clustering of cerebral corti-
cal lesions in patients with cor-
ticobasal degeneration. Neurosci
Lett (1999) 268:5–8. doi:10.1016/
S0304-3940(99)00309-2
91. Armstrong RA, Cairns NJ, Lan-
tos PL. What does the study
of the spatial patterns of patho-
logical lesions tell us about the
pathogenesis of neurodegenerative
disorders? Neuropathology (2001)
21:1–12. doi:10.1046/j.1440-1789.
2001.00373.x
92. Frost B, Jacks RL, Diamond
MI. Propagation of tau mis-
folding from the outside to
the inside of a cell. J Biol
Chem (2009) 284:12845–52. doi:
10.1074/jbc.M808759200
93. Novak P, Prcina M, Kontsekova
E. Tauons and prions: infa-
mous cousins? J Alzheimers Dis
(2011) 26:413–30. doi:10.3233/
JAD-2011-110194
94. Moreno-Gonzalez I, Soto C.
Misfolded protein aggregates:
mechanisms, structures
and potential for disease
transmission. Semin Cell
Dev Biol (2011) 22:482–7.
doi:10.1016/j.semcdb.2011.04.002
95. Lasagna-Reeves CA, Castillo-
Carranza DL, Sengupta U, Clos
AL, Jackson GR, Kayed R. Tau
oligomers impair memory and
induce synaptic and mitochondr-
ial dysfunction in wild-type mice.
Mol Neurodegener (2011) 6:39.
doi:10.1186/1750-1326-6-39
96. Lasagna-Reeves CA, Castillo-
Carranza DL, Sengupta U,
Guerrero-Munoz MJ, Kiritoshi T,
Neugebauer V, et al. Alzheimer
brain-derived tau oligomers prop-
agate pathology from endoge-
nous tau. Sci Rep (2012) 2:700.
doi:10.1038/srep00700
97. Lasagna-Reeves CA, Castillo-
Carranza DL, Sengupta U,
Sarmiento J, Troncoso J, Jack-
son GR, et al. Identification of
oligomers at early stages of tau
aggregation in Alzheimer’s dis-
ease. FASEB J (2012) 26:1946–59.
doi:10.1096/fj.11-199851
98. Liu L, Drouet V, Wu JW, Wit-
ter MP, Small SA, Clelland C,
et al. Trans-synaptic spread of
tau pathology in vivo. PLoS
One (2012) 7:e31302. doi:10.1371/
journal.pone.0031302
99. de Calignon A, Polydoro M,
Suarez-Calvet M, William C,
Adamowicz DH, Kopeikina KJ, et
al. Propagation of tau pathology
in a model of early Alzheimer’s
disease. Neuron (2012) 73:
685–97. doi:10.1016/j.neuron.
2011.11.033
100. Iba M, Guo JL, McBride JD,
Zhang B, Trojanowski JQ, Lee VM.
Synthetic tau fibrils mediate trans-
mission of neurofibrillary tangles
in a transgenic mouse model
of Alzheimer’s-like tauopathy. J
Neurosci (2013) 33(3):1024–37.
doi:10.1523/JNEUROSCI.2642-
12.2013
101. Legname G, Nguyen HO, Baskakov
IV, Cohen FE, Dearmond SJ,
Prusiner SB. Strain-specified char-
acteristics of mouse synthetic pri-
ons. Proc Natl Acad Sci U S A
(2005) 102:2168–73. doi:10.1073/
pnas.0409079102
102. Collinge J, Clarke AR. A gen-
eral model of prion strains
and their pathogenicity. Science
(2007) 318:930–6. doi:10.1126/
science.1138718
103. Hall GF, Lee S, Yao J. Neurofibril-
lary degeneration can be arrested
in an in vivo cellular model of
human tauopathy by application
Frontiers in Neurology | Neurodegeneration October 2013 | Volume 4 | Article 160 | 14
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gendreau and Hall Tangles, toxicity, and tau secretion
of a compound which inhibits tau
filament formation in vitro. J Mol
Neurosci (2002) 19:253–60. doi:10.
1385/JMN:19:3:251
104. Honson NS, Jensen JR, Abraha A,
Hall GF, Kuret J. Small-molecule
mediated neuroprotection in an
in situ model of tauopathy. Neuro-
tox Res (2009) 15:274–83. doi:10.
1007/s12640-009-9028-y
105. Kim W, Lee S, Jung C, Ahmed
A, Lee G, Hall GF. Interneuronal
transfer of human tau between
lamprey central neurons in situ. J
Alzheimers Dis (2010) 19:647–64.
doi:10.3233/JAD-2010-1273
106. Saman S, Kim W, Raya M, Visnick
Y, Miro S, Saman S, et al. Exosome-
associated tau is secreted in
tauopathy models and is selectively
phosphorylated in cerebrospinal
fluid in early Alzheimer disease.
J Biol Chem (2012) 287:3842–9.
doi:10.1074/jbc.M111.277061
107. Lashuel HA, Hartley D, Petre
BM, Walz T, Lansbury PT. Neu-
rodegenerative disease: amyloid
pores from pathogenic mutations.
Nature (2002) 418:291. doi:10.
1038/418291a
108. Flach K, Hilbrich I, Schiffmann A,
Gartner U, Kruger M, Leonhardt
M, et al. Tau oligomers impair
artificial membrane integrity
and cellular viability. J Biol
Chem (2012) 287:43223–33.
doi:10.1074/jbc.M112.396176
109. Amadoro G, Ciotti MT, Costanzi
M, Cestari V, Calissano P, Canu
N. NMDA receptor mediates tau-
induced neurotoxicity by cal-
pain and ERK/MAPK activation.
Proc Natl Acad Sci U S A
(2006) 103:2892–7. doi:10.1073/
pnas.0511065103
110. Bloom GS, Ren K, Glabe C. Cul-
tured cell and transgenic mouse
models for tau pathology linked
to beta-amyloid. Biochim Biophys
Acta (2005) 1739:116–24. doi:10.
1016/j.bbadis.2004.08.008
111. King ME, Kan H, Baas PW,
Erisir A, Glabe C, Bloom GS.
Tau-dependent microtubule dis-
assembly initiated by prefibril-
lar beta-amyloid. J Cell Biol
(2006) 175:541–6. doi:10.1083/jcb.
200605187
112. Ferreira A, Bigio EH. Calpain-
mediated tau cleavage: a
mechanism leading to neu-
rodegeneration shared by
multiple tauopathies. Mol
Med (2011) 17:676–85.
doi:10.2119/molmed.2010.00220
113. Braak E, Braak H, Mandelkow
EM. A sequence of cytoskeleton
changes related to the formation
of neurofibrillary tangles and neu-
ropil threads. Acta Neuropathol
(1994) 87:554–67. doi:10.1007/
BF00293315
114. McKee AC, Kowall NW, Kosik
KS. Microtubular reorganization
and dendritic growth response in
Alzheimer’s disease. Ann Neurol
(1989) 26(5):652–9. doi:10.1002/
ana.410260511
115. Crowther RA, Olesen OF, Jakes R,
Goedert M. The microtubule bind-
ing repeats of tau protein assem-
ble into filaments like those found
in Alzheimer’s disease. FEBS Lett
(1992) 309:199–202. doi:10.1016/
0014-5793(92)81094-3
116. Arawaka S, Usami M, Sahara N,
Schellenberg GD, Lee G, Mori H.
The tau mutation (val337met)
disrupts cytoskeletal networks
of microtubules. Neuroreport
(2000) 10(5):993–7. doi:10.1097/
00001756-199904060-00018
117. Hong M, Zhukareva V,Vogelsberg-
Ragaglia V, Wszolek Z, Reed L,
Miller BI, et al. Mutation-specific
functional impairments in distinct
tau isoforms of hereditary FTDP-
17. Science (1998) 282:1914–7.
doi:10.1126/science.282.5395.
1914
118. Perez M, Arrasate M, Montejo
de Garcini E, Munoz V, Avila J.
In vitro assembly of tau protein:
mapping the regions involved in
filament formation. Biochemistry
(2001) 40:5983–91. doi:10.1021/
bi002961w
119. Makrides V, Shen TE, Bhatia
R, Smith BL, Thimm J, Lal
R, et al. Microtubule-dependent
oligomerization of tau. Implica-
tions for physiological tau func-
tion and tauopathies. J Biol
Chem (2003) 278:33298–304. doi:
10.1074/jbc.M305207200
120. Sahara N, Tomiyama T, Mori
H. Missense point mutations of
tau to segregate with FTDP-17
exhibit site-specific effects on
microtubule structure in COS
cells: a novel action of R406W
mutation. J Neurosci Res (2000)
60(3):380–7. doi:10.1002/(SICI)
1097-4547(20000501)60:3<380:
:AID-JNR13>3.0.CO;2-5
121. Maeda S, Sahara N, Saito Y,
Murayama S, Ikai A, Takashima
A. Increased levels of granular tau
oligomers: an early sign of brain
aging and Alzheimer’s disease.
Neurosci Res (2006) 54:197–201.
doi:10.1016/j.neures.2005.11.009
122. Maeda S, Sahara N, Saito Y,
Murayama M, Yoshiike Y, Kim
H, et al. Granular tau oligomers
as intermediates of tau filaments.
Biochemistry (2007) 46:3856–61.
doi:10.1021/bi061359o
123. Kampers T, Friedhoff P, Biernat
J, Mandelkow EM, Mandelkow
E. RNA stimulates aggregation
of microtubule-associated protein
tau into Alzheimer-like paired heli-
cal filaments. FEBS Lett (1996)
399(3):344–9. doi:10.1016/S0014-
5793(96)01386-5
124. Wilson DM, Binder LI. Free fatty
acids stimulate the polymeriza-
tion of tau and amyloid beta pep-
tides. In vitro evidence for a com-
mon effector of pathogenesis in
Alzheimer’s disease. Am J Pathol
(1997) 150(6):2181–95.
125. Chirita CN, Congdon EE, Yin H,
Kuret J. Triggers of full-length tau
aggregation: a role for partially
folded intermediates. Biochemistry
(2005) 44:5862–72. doi:10.1021/
bi0500123
126. Gray EG, Paula-Barbosa M, Roher
A. Alzheimer’s disease: paired
helical filaments and cytomem-
branes. Neuropathol Appl Neu-
robiol (1987) 13:91–110. doi:10.
1111/j.1365-2990.1987.tb00174.x
127. Chirita CN, Kuret J. Evidence
for an intermediate in tau fil-
ament formation. Biochemistry
(2004) 43:1704–14. doi:10.1021/
bi036034b
128. Fulga TA, Elson-Schwab I, Khu-
rana V, Steinhilb ML, Spires
TL, Hyman BT, et al. Abnormal
bundling and accumulation of F-
actin mediates tau-induced neu-
ronal degeneration in vivo. Nat
Cell Biol (2007) 9:139–48. doi:10.
1038/ncb1528
129. Sharma VM, Litersky JM, Bhaskar
K, Lee G. Tau impacts on growth-
factor-stimulated actin remodel-
ing. J Cell Sci (2007) 120:748–57.
doi:10.1242/jcs.03378
130. Hall GF, Chu B, Lee G, Yao
J. Human tau filaments induce
microtubule and synapse loss in
an in vivo model of neurofibril-
lary degenerative disease. J Cell Sci
(2000) 113(Pt 8):1373–87.
131. Lee S, Jung C, Lee G, Hall GF.
Exonic point mutations of human
tau enhance its toxicity and cause
characteristic changes in neuronal
morphology, tau distribution and
tau phosphorylation in the lam-
prey cellular model of tauopathy.
J Alzheimers Dis (2009) 16:99–111.
doi:10.3233/JAD-2009-0954
132. Liazoghli D, Perreault S, Micheva
KD, Desjardins M, Leclerc N.
Fragmentation of the Golgi
apparatus induced by overex-
pression of WT and mutant
human tau forms in neurons. Am
J Pathol (2005) 166:1499–514.
doi:10.1016/S0002-9440(10)
62366-8
133. Farah CA, Perreault S, Liazoghli
D, Desjardins M, Anton A, Lau-
zon M, et al. Tau interacts
with Golgi membranes and medi-
ates their association with micro-
tubules. Cell Motil Cytoskeleton
(2006) 63:710–24. doi:10.1002/
cm.20157
134. Santa-Maria I, Varghese M,
Ksiezak-Reding H, Dzhun A,
Wang J, Pasinetti GM. Paired
helical filaments from Alzheimer
disease brain induce intra-
cellular accumulation of tau
protein in aggresomes. J Biol
Chem (2012) 287:20522–33.
doi:10.1074/jbc.M111.323279
135. Mori H, Kondo J, Ihara Y. Ubiqui-
tin is a component of paired heli-
cal filaments in Alzheimer’s dis-
ease. Science (1987) 235:1641–4.
doi:10.1126/science.3029875
136. Hamano T, Gendron TF, Causevic
E, Yen SH, Lin WL, Isidoro C, et
al. Autophagic-lysosomal pertur-
bation enhances tau aggregation in
transfectants with induced wild-
type tau expression. Eur J Neurosci
(2008) 27:1119–30. doi:10.1111/j.
1460-9568.2008.06084.x
137. Braak E, Braak H. Alzheimer’s dis-
ease: transiently developing den-
dritic changes in pyramidal cells of
sector CA1 of the Ammon’s horn.
Acta Neuropathol (1997) 93:323–5.
doi:10.1007/s004010050622
138. Hall GF, Yao J, Lee G. Human
tau becomes phosphorylated and
forms filamentous deposits when
overexpressed in lamprey central
neurons in situ. Proc Natl Acad Sci
U S A (1997) 94:4733–8. doi:10.
1073/pnas.94.9.4733
139. Blazquez-Llorca L, Garcia-Marin
V, Merrino-Serrais P, Avila J, DeFe-
lipe J. Abnormal tau phosphory-
lation in the thorny excrescences
of CA3 hippocampal neurons in
patients with Alzheimer’s disease.
J Alzheimers Dis (2011) 26:683–98.
doi:10.3233/JAD-2011-110659
140. Shemesh OA, Erez H, Ginzburg
I, Spira ME. Tau-induced traffic
jams reflect organelles accumu-
lation at points of microtubule
polar mismatching. Am J Pathol
(2008) 172(6):1683–92. doi:10.
1111/j.1600-0854.2007.00695.x
141. Müller W, Eckert A, Kurz C, Eck-
ert G, Leuner K. Mitochondrial
dysfunction: common final path-
way in brain aging and Alzheimer’s
disease – therapeutic aspects. Mol
Neurobiol (2010) 41(2–3):159–71.
doi:10.1007/s12035-010-8141-5
www.frontiersin.org October 2013 | Volume 4 | Article 160 | 15
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gendreau and Hall Tangles, toxicity, and tau secretion
142. Hall GF, Lee S, Ferreira A,
Lee G. Mitochondrial clump-
ing is a central feature in the
tau neurodegeneration mecha-
nism in an in situ tauopathy
model. Alzheimers Dement (2008)
4(4 Suppl):T184. doi:10.1016/j.
jalz.2008.05.503
143. Greenwood SM, Mizielinska SM,
Frenguelli BG, Harvey J, Connolly
CN. Mitochondrial dysfunction
and dendritic beading during
neuronal toxicity. J Biol Chem
(2007) 282(36):26235–44. doi:10.
1074/jbc.M704488200
144. Baum L, Seger R, Woodgett JR,
Kawabata S, Maruyama K, Koyama
M, et al. Overexpressed tau protein
in cultured cells is phosphorylated
without formation of PHF: impli-
cation of phosphoprotein phos-
phatase involvement. Mol Brain
Res (1995) 34:1–17. doi:10.1016/
0169-328X(95)00111-5
145. Iliev AI, Ganesan S, Bunt
G, Wouters FS. Removal of
pattern-breaking sequences in
microtubule binding repeats
produces instantaneous tau
aggregation and toxicity. J Biol
Chem (2006) 281:37195–204.
doi:10.1074/jbc.M604863200
146. Khlistunova I, Biernat J, Wang
Y, Pickhardt M, von Bergen M,
Gazova Z, et al. Inducible expres-
sion of tau repeat domain in
cell models of tauopathy: aggre-
gation is toxic to cells but can
be reversed by inhibitor drugs. J
Biol Chem (2006) 281(2):1205–14.
doi:10.1074/jbc.M507753200
147. Wittmann CW, Wszolek MF, Shul-
man JM, Salvaterra PM, Lewis
J, Hutton M, et al. Tauopathy
in Drosophila: neurodegeneration
without neurofibrillary tangles.
Science (2001) 293(5530):711–4.
doi:10.1126/science.1062382
148. Bobinski M,Wegiel J, Tarnawski M,
Bobinski M, Reisberg B, de Leon
MJ, et al. Relationships between
regional neuronal loss and neu-
rofibrillary changes in the hip-
pocampal formation and dura-
tion and severity of Alzheimer
disease. J Neuropathol Exp Neu-
rol (1997) 56:414–20. doi:10.1097/
00005072-199704000-00010
149. Morsch R, Simon W, Cole-
man PD. Neurons may live for
decades with neurofibrillary tan-
gles. J Neuropathol Exp Neu-
rol (1999) 58:188–97. doi:10.1097/
00005072-199902000-00008
150. Coleman PD, Flood DG. Neuron
numbers and dendrite extent in
normal aging and Alzheimer’s
disease. Neurobiol Aging (1987)
8:521–45. doi:10.1016/0197-
4580(87)90127-8
151. Santacruz K, Lewis J, Spires T, Paul-
son J, Kotilinek L, Ingelsson M, et
al. Tau suppression in a neurode-
generative mouse memory func-
tion. Science (2005) 309:476–81.
doi:10.1126/science.1113694
152. Spires TL, Orne JD, SantaCruz K,
Pitstick R, Carlson GA,Ashe KH, et
al. Region-specific dissociation of
neuronal loss and neurofibrillary
pathology in a mouse model of
tauopathy. Am J Pathol (2006)
168:1598–607. doi:10.2353/ajpath.
2006.050840
153. Sydow A, Van der Jeugd A, Zheng
F, Ahmed T, Balschun D, Petrova
O, et al. Tau-induced defects in
synaptic plasticity, learning, and
memory are reversible in trans-
genic mice after switching off
the toxic tau mutant. J Neurosci
(2011) 31:2511–25. doi:10.1523/
JNEUROSCI.5245-10.2011
154. Kopeikina KJ, Carlson GA, Pit-
stick R, Ludvigson AE, Peters A,
Luebke JI, et al. Tau accumula-
tion causes mitochondrial distri-
bution deficits in neurons in a
mouse model of tauopathy and in
human Alzheimer’s disease brain.
Am J Pathol (2011) 179:2071–82.
doi:10.1016/j.ajpath.2011.07.004
155. Spittaels K, Van den Haute C,
Van Dorpe J, Bruynseels K, Van-
dezande K, Laenen I, et al. Promi-
nent axonopathy in the brain
and spinal cord of transgenic
mice overexpressing four-repeat
human tau protein. Am J Pathol
(1999) 155(6):2153–65. doi:10.
1016/S0002-9440(10)65533-2
156. Kowall NW, Kosik KS. Axonal
disruption and aberrant local-
ization of tau protein charac-
terize the neuropil pathology of
Alzheimer’s disease. Ann Neu-
rol (1987) 22:639–43. doi:10.1002/
ana.410220514
157. Gotz J, Ittner LM, Fandrich M,
Schonrock N. Is tau aggregation
toxic or protective: a sensible ques-
tion in the absence of sensitive
methods? J Alzheimers Dis (2008)
14(4):423–9.
158. Castellani RJ, Nunomura A, Lee
HG, Perry G, Smith MA. Phos-
phorylated tau: toxic, protective, or
none of the above. J Alzheimers Dis
(2008) 14(4):377–83.
159. Yeh P, Chang C. Phosphorylation
alters tau distribution and elon-
gates life span in Drosophila. J
Alzheimers Dis (2010) 21:543–56.
doi:10.3233/JAD-2010-091678
160. Andorfer C, Acker CM, Kress
Y, Hof PR, Duff K, Davies P.
Cell-cycle reentry and cell death
in transgenic mice expressing
nonmutant human tau isoforms.
J Neurosci (2005) 25:5446–54.
doi:10.1523/JNEUROSCI.4637-
04.2005
161. Mocanu MM, Nissen A, Ecker-
mann K, Khlistunova I, Biernat
J, Drexler D, et al. The poten-
tial for beta-structure in the repeat
domain of tau protein deter-
mines aggregation, synaptic decay,
neuronal loss, and coassembly
with endogenous tau in inducible
mouse models of tauopathy. J
Neurosci (2008) 28:737–48. doi:10.
1523/JNEUROSCI.2824-07.2008
162. Berger Z, Roder H, Hanna A, Carl-
son A, Rangachari V, Yue M, et al.
Accumulation of pathological tau
species and memory loss in a con-
ditional model of tauopathy. JNeu-
rosci (2007) 27:3650–62. doi:10.
1523/JNEUROSCI.0587-07.2007
163. Bucciantini M, Giannoni E, Chiti
F, Baroni F, Formigli L, Zurdo J,
et al. Inherent toxicity of aggre-
gates implies a common mecha-
nism for protein misfolding dis-
eases. Nature (2002) 416:507–11.
doi:10.1038/416507a
164. Kayed R, Sokolov Y, Edmonds B,
McIntire TM, Milton SC, Hall JE, et
al. Permeabilization of lipid bilay-
ers is a common conformation-
dependent activity of soluble amy-
loid oligomers in protein mis-
folding diseases. J Biol Chem
(2004) 279:46363–6. doi:10.1074/
jbc.C400260200
165. Hall GF, Lee VM, Lee G, Yao J.
Staging of neurofibrillary degener-
ation caused by human tau overex-
pression in a unique cellular model
of human tauopathy. Am J Pathol
(2001) 158:235–46. doi:10.1016/
S0002-9440(10)63962-4
166. Zehe C, Engling A, Wegehin-
gel S, Schafer T, Nickel W.
Cell-surface heparan sulfate pro-
teoglycans are essential com-
ponents of the unconventional
export machinery of FGF-2. Proc
Natl Acad Sci U S A (2006)
103:15479–84. doi:10.1073/pnas.
0605997103
167. Chiesa R, Piccardo P, Quaglio E,
Drisaldi B, Si-Hoe SL, Takao M, et
al. Molecular distinction between
pathogenic and infectious proper-
ties of the prion protein. J Virol
(2003) 77(13):7611–22. doi:10.
1128/JVI.77.13.7611-7622.2003
168. Chesebro B, Trifilo M, Race R,
Meade-White K, Teng C, LaCasse
R, et al. Anchorless prion pro-
tein results in infectious amyloid
disease without clinical scrapie.
Science (2005) 308(5727):1435–9.
doi:10.1126/science.1110837
169. Clavaguera F, Bolmont T,
Crowther RA, Abramowski D,
Frank S, Probst A, et al. Transmis-
sion and spreading of tauopathy
in transgenic mouse brain. Nat
Cell Biol (2009) 11:909–13.
doi:10.1038/ncb1901
170. Funk KE, Mrak RE, Kuret J. Gran-
ulovacuolar degeneration (GVD)
bodies of Alzheimer’s disease (AD)
resemble late-stage autophagic
organelles. Neuropathol Appl Neu-
robiol (2011) 37:295–306. doi:10.
1111/j.1365-2990.2010.01135.x
171. Funk KE, Kuret J. Lysosomal
fusion dysfunction as a unifying
hypothesis for Alzheimer’s disease
pathology. Int J Alzheimers Dis
(2012) 2012:752894. doi:10.1155/
2012/752894
172. Bendiske J, Bahr BA. Lysoso-
mal activation is a compensatory
response against protein accu-
mulation and associated synap-
topathogenesis – an approach
for slowing Alzheimer disease? J
Neuropathol Exp Neurol (2003)
62(5):451–63.
173. Winslow AR, Rubinsztein DC.
Autophagy in neurodegeneration
and development. Biochem Bio-
phys Acta (2008) 1782:723–9. doi:
10.1016/j.bbadis.2008.06.010
174. Lim F, Hernandez F, Lucas JJ,
Gomez-Ramos P, Moran MA,Avila
J. FTDP-17 mutations in tau
transgenic mice provoke lysoso-
mal abnormalities and tau fila-
ments in forebrain. Mol Cell Neu-
rosci (2001) 18:702–14. doi:10.
1006/mcne.2001.1051
175. LaPointe NE, Morfini G, Pigino G,
Gaisina IN, Kozikowski AP, Binder
LI, et al. The amino terminus
of tau inhibits kinesin dependent
axonal transport: implications for
filament toxicity. J Neurosci Res
(2009) 87:440–51. doi:10.1002/jnr.
21850
176. Boland B, Kumar A, Lee S,
Platt FM, Wegiel J, Yu WH, et
al. Autophagy induction and
autophagosome clearance in neu-
rons: relationship to autophagic
pathology in Alzheimer’s disease.
J Neurosci (2008) 28:6926–37.
doi:10.1523/JNEUROSCI.0800-
08.2008
177. Wang YP, Martinez-Vincente M,
Kruger U, Kaushik S, Wong E,
Mandelkow E, et al. Tau frag-
mentation, aggregation and clear-
ance: the dual role of lysoso-
mal processing. Hum Mol Genet
(2009) 18:4153–70. doi:10.1093/
hmg/ddp367
Frontiers in Neurology | Neurodegeneration October 2013 | Volume 4 | Article 160 | 16
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gendreau and Hall Tangles, toxicity, and tau secretion
178. Lee JH, Yu WH, Kumar A,
Lee S, Mohan PS, Peterhoff
CM, et al. Lysosomal proteoly-
sis and autophagy require pre-
senilin 1 and are disrupted by
Alzheimer-related PS1 mutations.
Cell (2010) 141(7):1146–58. doi:
10.1016/j.cell.2010.05.008
179. Gomez-Ramos A, Diaz-
Hernandez M, Cuadros R,
Hernandez F, Avila J. Extracellular
tau is toxic to neuronal cells.
FEBS Lett (2006) 580:4842–50.
doi:10.1016/j.febslet.2006.07.078
180. Gomez-Ramos A, Diaz-
Hernandez M, Rubio A, Miras-
Portugal MT, Avila J. Extracel-
lular tau promotes intracellular
calcium increase through M1
and M3 muscarinic receptors
in neuronal cells. Mol Cell
Neurosci (2008) 37:673–81.
doi:10.1016/j.mcn.2007.12.010
181. Gomez-Ramos A, Diaz-
Hernandez M, Rubio A, Diaz-
Hernandez JI, Miras-Portugal
MT, Avila J. Characteristics and
consequences of muscarinic
receptor activation by tau pro-
tein. Eur Neuropsychopharmacol
(2009) 19:708–17. doi:10.1016/j.
euroneuro.2009.04.006
182. Diaz-Hernandez M, Gomez-
Ramos A, Rubio A, Gomez-
Villafuertes R, Naranjo JR,
Miras-Portugal MT, et al. Tissue-
nonspecific alkaline phosphatase
promotes the neurotoxicity
effect of extracellular tau. J Biol
Chem (2010) 285:32539–48.
doi:10.1074/jbc.M110.145003
183. Armstrong RA, Cairns NJ, Lan-
tos PL. Clustering of Pick bod-
ies in Pick’s disease. Neurosci
Lett (1998) 242:81–4. doi:10.1016/
S0304-3940(98)00052-4
184. Amadoro G, Corsetti V, Stringaro
A, Colone M, D’Aguanno S, Meli
G, et al. A NH2 tau fragment tar-
gets neuronal mitochondria at AD
synapses: possible implication for
neurodegeneration. J Alzheimers
Dis (2010) 21:445–70. doi:10.
3233/JAD-2010-100120
185. Park S, Ferreira A. The generation
of a 17 kDa neurotoxic fragment:
an alternative mechanism by
which tau mediates a-amyloid-
induced neurodegeneration. J
Neurosci (2005) 25:5365–75.
doi:10.1523/JNEUROSCI.1125-
05.2005
186. Reinecke JB, DeVos SL, McGrath
JP, Shepard AM, Goncharoff DK,
Tait DN, et al. Implicating calpain
in tau-mediated toxicity in vivo.
PLoS One (2011) 6:e23865. doi:10.
1371/journal.pone.0023865
187. Garg S, Timm T, Mandelkow EM,
Mandelkow E, Wang Y. Cleavage
of tau by calpain in Alzheimer’s
disease: the quest for the toxic
17kD fragment. Neurobiol Aging
(2011) 32:1–14. doi:10.1016/j.
neurobiolaging.2010.09.008
188. Atlante A, Amadoro G, Bobba
A, de Bari L, Corsetti V, Pap-
palardo G, et al. A peptide contain-
ing residues 26-44 of tau protein
impairs mitochondrial oxidative
phosphorylation acting at the
level of the adenine nucleotide
translocator. Biochim Biophys Acta
(2008) 1777:1289–300. doi:10.
1016/j.bbabio.2008.07.004
189. Amadoro G, Serafino AL, Barbato
C, Ciotti MT, Sacco A, Calissano
P, et al. Role of N-terminal tau
domain integrity on the survival
of cerebellar granule neurons. Cell
Death Differ (2004) 11(2):217–30.
doi:10.1038/sj.cdd.4401314
190. Corsetti V, Amadoro G, Gentile
A, Capsoni S, Ciotti MT, Cen-
cioni MT, et al. Identification of
a caspase-derived N-terminal tau
fragment in cellular and animal
Alzheimer’s disease models. Mol
Cell Neurosci (2008) 38:381–92.
doi:10.1016/j.mcn.2008.03.011
191. Hernandez F, Avila J. Tau
aggregates and tau pathol-
ogy. J Alzheimers Dis (2008)
14(4):449–52.
192. Cowan CM, Sealey MA, Quraishe
S, Targett MT, Marcellus K, Allan
D, et al. Modelling tauopathies
in Drosophila: insights from the
fruit fly. J Alzheimers Dis (2011)
15(4):541–53. doi:10.4061/2011/
598157
193. Klein WL, Stine WB Jr, Teplow
DB. Small assemblies of unmod-
ified amyloid beta-protein are
the proximate neurotoxin in
Alzheimer’s disease. Neuro-
biol Aging (2004) 25:569–80.
doi:10.1016/j.neurobiolaging.
2004.02.010
194. Hall GF, Patuto BA. Is tau now
ready for admission to the prion
club? Prion (2012) 6(3):223–33.
doi:10.4161/pri.19912
195. Kim W, Lee S, Hall GF. Secretion
of human tau fragments resem-
bling CSF-tau in Alzheimer’s dis-
ease is modulated by the presence
of the exon 2 insert. FEBS Lett
(2010) 584:3085–8. doi:10.1016/j.
febslet.2010.05.042
196. Emmanouilidou E, Melachroinou
K, Roumeliotis T, Garbis SD,
Ntzouni M, Margaritis LH, et al.
Cell-produced alpha-synuclein is
secreted in a calcium-dependent
manner by exosomes and impacts
neuronal survival. J Neurosci
(2010) 30:6838–51. doi:10.1523/
JNEUROSCI.5699-09.2010
197. Fevrier B, Vilette D, Archer F, Loew
D, Faigle W, Vidal M, et al. Cells
release prions in association with
exosomes. Proc Natl Acad Sci U S
A (2004) 101:9683–8. doi:10.1073/
pnas.0308413101
198. Rajendran L, Honsho M, Zahn TR,
Keller P, Geiger KD,Verkade P, et al.
Alzheimer’s disease beta-amyloid
peptides are released in association
with exosomes. Proc Natl Acad Sci
U S A (2006) 103:11172–7. doi:10.
1073/pnas.0603838103
199. Hall GF, Saman S. Death or secre-
tion? The demise of a plausi-
ble assumption about CSF-tau in
Alzheimer disease?Commun Integr
Biol (2012) 5(6):623–6. doi:10.
4161/cib.21437
200. Johnson GV, Seubert P, Cox TM,
Motter R, Brown JP, Galasko D.
The tau protein in human cere-
brospinal fluid in Alzheimer’s dis-
ease consists of proteolytically
derived fragments. J Neurochem
(1997) 68:430–3. doi:10.1046/j.
1471-4159.1997.68010430.x
201. Barten DM, Cadelina GW, Hoque
N, DeCarr LB, Guss VL, Yang L,
et al. Tau transgenic mice as mod-
els for cerebrospinal fluid tau bio-
markers. J Alzheimers Dis (2011)
24(Suppl 2):127–41. doi:10.3233/
JAD-2011-110161
202. Yamada K, Cirrito JR, Stewart FR,
Jiang H, Finn MB, Holmes BB,
et al. In vivo microdialysis reveals
age-dependent decrease of brain
interstitial fluid tau levels in P301S
human tau transgenic mice. J Neu-
rosci (2011) 31:13110–7. doi:10.
1523/JNEUROSCI.2569-11.2011
203. Plouffe V, Mohamed NV, Rivest-
McGraw J, Bertrand J, Lauzon M,
Leclerc N. Hyperphosphorylation
and cleavage at D421 enhance
tau secretion. PLoS One (2012)
7:e36873. doi:10.1371/journal.
pone.0036873
204. Chai X, Dage JL, Citron M. Con-
stitutive secretion of tau protein
by an unconventional mechanism.
Neurobiol Dis (2012) 48:356–66.
doi:10.1016/j.nbd.2012.05.021
205. Faure J, Lachenal G, Court M,
Hirrlinger J, Chatellard-Causse C,
Blot B, et al. Exosomes are released
by cultured cortical neurons. Mol
Cell Neurosci (2006) 31:642–8. doi:
10.1016/j.mcn.2005.12.003
206. Simon D, Garcia-Garcia E, Royo
F, Falcon-Perez JM, Avila J. Pro-
teostasis of tau. Tau overexpres-
sion results in its secretion via
membrane vesicles. FEBS Lett
(2012) 586:47–54. doi:10.1016/j.
febslet.2011.11.022
207. Abrahamsen H, Stenmark H. Pro-
tein secretion: unconventional exit
by exophagy. Curr Biol (2011)
20:R4–8. doi:10.1016/j.cub.2010.
03.011
208. Patterson KR, Remmers C, Fu
Y, Brooker S, Kanaan NM, Vana
L, et al. Characterization of pre-
fibrillar tau oligomers in vitro
and in Alzheimer disease. J Biol
Chem (2011) 286:23063–76. doi:
10.1074/jbc.M111.237974
209. Wu JW, Herman M, Liu L, Simoes
S, Acker CM, Figueroa H, et al.
Small misfolded tau species are
internalized via bulk endocyto-
sis and anterogradely and retro-
gradely transported in neurons.
J Biol Chem (2013) 288:1856–70.
doi:10.1074/jbc.M112.394528
210. Busciglio J, Lorenzo A, Yeh J,
Yankner BA. Beta-amyloid fib-
rils induce tau phosphorylation
and loss of microtubule binding.
Neuron (1995) 14:879–88. doi:10.
1016/0896-6273(95)90232-5
211. van’t Hof W, Resh MD. Rapid
plasma membrane anchoring
of newly synthesized p59 fyn:
selective requirement for NH2-
terminal myristoylation and
palmitoylation at cysteine-3. J
Cell Biol (1997) 136(5):1023–35.
doi:10.1083/jcb.136.5.1023
212. Freedman SD, Katz MH, Parker
EM, Gelrud A. Endocytosis at the
apical plasma membrane of pan-
creatic acinar cells is regulated
by tyrosine kinases. Am J Physiol
(1999) 276(2 Pt 1):C306–11.
213. Sverdlov M, Shajahan AN,
Minshall RD. Tyrosine
phosphorylation-dependence
of caveolae-mediated endocytosis.
J Cell Mol Med (2007) 11:1239–50.
doi:10.1111/j.1582-4934.2007.
00127.x
214. Riento K, Frick M, Schafer
I, Nichols BJ. Endocytosis of
flotillin-1 and flotillin-2 is regu-
lated by fyn kinase. J Cell Sci (2009)
122:912–8. doi:10.1242/jcs.039024
215. Chee FC, Mudher A, Cuttle MF,
Newman TA, MacKay D, Love-
stone S, et al. Over-expression of
tau results in defective synaptic
transmission in Drosophila neuro-
muscular junctions. Neurobiol Dis
(2005) 20:918–28. doi:10.1016/j.
nbd.2005.05.029
216. Roberson ED, Scearce-Levie K,
Palop JJ, Yan F, Cheng IH, Wu
T, et al. Reducing endogenous
tau ameliorates amyloid beta-
induced deficits in an Alzheimer’s
disease mouse model. Science
www.frontiersin.org October 2013 | Volume 4 | Article 160 | 17
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gendreau and Hall Tangles, toxicity, and tau secretion
(2007) 316:750–4. doi:10.1126/
science.1141736
217. Yoshiyama Y, Higuchi M, Zhang B,
Huang SM, Iwata N, Saido TC, et
al. Synapse loss and microglial acti-
vation precede tangles in a P301S
tauopathy mouse model. Neuron
(2007) 53(3):337–51. doi:10.1016/
j.neuron.2007.01.010
218. Shipton O, Leitz J, Dworzak J,
Acton CE, Tunbridge EM, Denk
F, et al. Tau protein is required
for amyloid-induced impair-
ment of hippocampal long-term
potentiation. J Neurosci (2011)
31(5):1688–92. doi:10.1523/
JNEUROSCI.2610-10.2011
219. Shehata M, Matsumura H, Okubo-
Suzuki R, Ohkawa N, Inokuchi
K. Neuronal stimulation induces
autophagy in hippocampal neu-
rons that is involved in AMPA
receptor degradation after chem-
ical long-term depression. J Neu-
rosci (2012) 32:10413–22. doi:10.
1523/JNEUROSCI.4533-11.2012
220. Dobrowolski R, Vick P, Ploper
D, Gumper I, Snitkin H, Saba-
tini DD, et al. Presenilin defi-
ciency or lysosomal inhibition
enhance Wnt signaling through
relocalization of GSK3 to the late
endosomal compartment. Cell Rep
(2012) 2:1316–28. doi:10.1016/j.
celrep.2012.09.026
221. Murakami N, Oyama F, Gu Y,
McLennan IS, Nonaka I, Ihara Y.
Accumulation of tau in autophagic
vacuoles in chloroquine myopa-
thy. J Neuropathol Exp Neurol
(1998) 57(7):664–73. doi:10.1097/
00005072-199807000-00003
222. Kikuchi A, Yamamoto H, Kisheda
S. Multiplicity of the interactions
of Wnt proteins and their recep-
tors. Cell Signal (2007) 19:659–71.
doi:10.1016/j.cellsig.2006.11.001
223. Boonen RA, van Tijn P, Zivkovic
D. Wnt signaling in Alzheimer’s
disease: up or down, that is
the question. Ageing Res Rev
(2009) 8:71–82. doi:10.1016/j.arr.
2008.11.003
224. Wei J, Liu W, Yan Z. Regu-
lation of AMPA receptor traf-
ficking and function by glyco-
gen synthase kinase 3. J Biol
Chem (2010) 285:26369–76. doi:
10.1074/jbc.M110.121376
225. Yamamoto H, Komekado H,
Kikuchi A. Caveolin is necessary
for Wnt-3a-dependent internal-
ization of LRP6 and beta-catenin.
Dev Cell (2006) 11:213–23.
doi:10.1016/j.devcel.2006.07.003
226. Taelman VF, Dobrowolski R,
Plouhinec JL, Fuentealba LC,
Vorwald PP, Gumper I, et al. Wnt
signaling requires sequestration
of glycogen synthase kinase
3 inside multivesicular endo-
somes. Cell (2010) 143:1136–48.
doi:10.1016/j.cell.2010.11.034
227. Beattie EC, Carroll RC, Yu X, Mor-
ishita W,Yasuda H, von Zastrow M,
et al. Regulation of AMPA receptor
endocytosis by a signaling mecha-
nism shared with LTD. Nat Neu-
rosci (2000) 3:1291–300. doi:10.
1038/81823
228. Hayashi T, Huganir RL. Tyrosine
phosphorylation and regulation of
the AMPA receptor by src fam-
ily tyrosine kinases. J Neurosci
(2004) 24:6152–60. doi:10.1523/
JNEUROSCI.0799-04.2004
229. Chivet M, Hemming F, Pernet-
Gallay K, Fraboulet S, Sadoul R.
Emerging role of neuronal exo-
somes in the central nervous sys-
tem. Front Physiol (2012) 3:145.
doi:10.3389/fphys.2012.00145
230. Lachenal G, Pernet-Gallay K,
Chivet M, Hemming FJ, Belly A,
Bodon G,et al. Release of exosomes
from differentiated neurons and
its regulation by synaptic gluta-
matergic activity.Mol Cell Neurosci
(2010) 46:409–18. doi:10.1016/j.
mcn.2010.11.004
231. Pooler AM, Phillips EC, Lau DHW,
Noble W, Hanger DP. Physiological
release of endogenous tau is stim-
ulated by neuronal activity. EMBO
Rep (2013) 14(4):389–94. doi:10.
1038/embor.2013.15
232. Hoover BR, Reed MN, Su J, Pen-
rod RD, Kotilinek LA, Grant MK,
et al. Tau mislocalization to den-
dritic spines mediates synaptic
dysfunction independently of neu-
rodegeneration. Neuron (2010)
68:1067–81. doi:10.1016/j.neuron.
2010.11.030
233. Fang Y, Wu N, Gan X, Yan W,
Morrell JC, Gould SJ. Higher-order
oligomerization targets plasma
membrane proteins and HIB gag
to exosomes. PLoS Biol (2007)
5:e158. doi:10.1371/journal.pbio.
0050158
234. Gotz J, Probst A, Spillantini MG,
Schafer T, Jakes R, Burki K, et al.
Somatodendritic localization and
hyperphosphorylation of tau pro-
tein in transgenic mice express-
ing the longest human brain
tau isoform. EMBO J (1995)
14(7):1304–13.
235. Brion JP, Tremp G, Octave JN.
Transgenic expression of the short-
est human tau affects its compart-
mentalization and its phosphory-
lation as in the pretangle stage
of Alzheimer’s disease. Am J Path
(1999) 154:255–70. doi:10.1016/
S0002-9440(10)65272-8
236. Tackenberg C, Brandt R. Diver-
gent pathways mediate spine alter-
ations and cell death induced
by amyloid-beta, wild-type tau,
and R406W tau. J Neurosci
(2009) 29:14439–50. doi:10.1523/
JNEUROSCI.3590-09.2009
237. Antonell A, Lladó A, Altirriba J,
Botta-Orfila T, Balasa M, Fer-
nández M, et al. A preliminary
study of the whole-genome
expression profile of sporadic and
monogenic early-onsetalzheimer’s
disease. Neurobiol Aging (2013)
34(7):1772–8. doi:10.1016/j.
neurobiolaging.2012.12.026
238. Blalock EM, Geddes JW, Chen
KC, Porter NM, Markesbery
WR, Landfield PW. Incipient
Alzheimer’s disease: microarray
correlation analyses reveal major
transcriptional and tumor sup-
pressor responses. Proc Natl Acad
Sci U S A (2004) 101:2173–8.
doi:10.1073/pnas.0308512100
239. Mathivanan S, Simpson RJ. Exo-
Carta: a compendium of exoso-
mal proteins and RNA. Proteomics
(2009) 9(21):4997–5000. doi:10.
1002/pmic.200900351
Conflict of Interest Statement: The
authors declare that the research was
conducted in the absence of any com-
mercial or financial relationships that
could be construed as a potential con-
flict of interest.
Received: 01 July 2013; paper pending
published: 12 July 2013; accepted: 26 Sep-
tember 2013; published online: 21 Octo-
ber 2013.
Citation: Gendreau KL and Hall GF
(2013) Tangles, toxicity, and tau secre-
tion in AD – new approaches to a vex-
ing problem. Front. Neurol. 4:160. doi:
10.3389/fneur.2013.00160
This article was submitted to Neurode-
generation, a section of the journal Fron-
tiers in Neurology.
Copyright © 2013 Gendreau and Hall.
This is an open-access article distributed
under the terms of the Creative Com-
mons Attribution License (CC BY). The
use, distribution or reproduction in other
forums is permitted, provided the origi-
nal author(s) or licensor are credited and
that the original publication in this jour-
nal is cited, in accordance with accepted
academic practice. No use, distribution or
reproduction is permitted which does not
comply with these terms.
Frontiers in Neurology | Neurodegeneration October 2013 | Volume 4 | Article 160 | 18
